<SEC-DOCUMENT>0001493152-23-027344.txt : 20230809
<SEC-HEADER>0001493152-23-027344.hdr.sgml : 20230809
<ACCEPTANCE-DATETIME>20230809160541
ACCESSION NUMBER:		0001493152-23-027344
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230809
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230809
DATE AS OF CHANGE:		20230809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HARROW HEALTH, INC.
		CENTRAL INDEX KEY:			0001360214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450567010
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35814
		FILM NUMBER:		231155092

	BUSINESS ADDRESS:	
		STREET 1:		102 WOODMONT BLVD
		STREET 2:		SUITE 610
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37215
		BUSINESS PHONE:		615.733.4731

	MAIL ADDRESS:	
		STREET 1:		102 WOODMONT BLVD
		STREET 2:		SUITE 610
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37215

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Imprimis Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20120301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSDEL PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20070912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bywater Resources, Inc
		DATE OF NAME CHANGE:	20060421
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:hrow="http://harrow.com/20230809">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_hrow_harrow.com_20230809 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20230809_20230809 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001360214 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:EntityCentralIndexKey">0001360214</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="hrow-20230809.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-08-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-09</xbrli:startDate>
        <xbrli:endDate>2023-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-092023-08-09_custom_CommonStock0.001ParValuePerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrow:CommonStock0.001ParValuePerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-09</xbrli:startDate>
        <xbrli:endDate>2023-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-092023-08-09_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrow:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-09</xbrli:startDate>
        <xbrli:endDate>2023-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-092023-08-09_custom_Sec11.875SeniorNotesDue2027Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrow:Sec11.875SeniorNotesDue2027Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-09</xbrli:startDate>
        <xbrli:endDate>2023-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: Black"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><b>FORM
<span id="xdx_90A_edei--DocumentType_c20230809__20230809_zLf7dTeWKr42"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Date
of Report (Date of earliest event reported): <span id="xdx_90A_edei--DocumentPeriodEndDate_c20230809__20230809_z7UaMU7hwm2j"><ix:nonNumeric contextRef="AsOf2023-08-09" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 9, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><b><span id="xdx_901_edei--EntityRegistrantName_c20230809__20230809_zKqxw7E6xUC4"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:EntityRegistrantName">HARROW
HEALTH, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20230809__20230809_zxBHhrPJ7sDf"><ix:nonNumeric contextRef="AsOf2023-08-09" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_901_edei--EntityFileNumber_c20230809__20230809_zktatMuUAOm8"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:EntityFileNumber">001-35814</ix:nonNumeric></span></b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20230809__20230809_z3XbsXoomQll"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:EntityTaxIdentificationNumber">45-0567010</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">of
    incorporation)</span></p></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">File
    Number)</span></p></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(IRS
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20230809__20230809_zhd3nykrvy84"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:EntityAddressAddressLine1">102
    Woodmont Blvd.</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20230809__20230809_z4SxlVA22hX5"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:EntityAddressAddressLine2">Suite 610</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_90E_edei--EntityAddressCityOrTown_c20230809__20230809_zOQlT2dXLxb1"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:EntityAddressCityOrTown">Nashville</ix:nonNumeric></span>,
    <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20230809__20230809_zblXUruOoqta"><ix:nonNumeric contextRef="AsOf2023-08-09" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Tennessee</ix:nonNumeric> </span></b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20230809__20230809_zc5t6Et92Lde"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:EntityAddressPostalZipCode">37205</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Address
    of principal executive offices)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Registrant&#8217;s
telephone number, including area code: <b><span id="xdx_909_edei--CityAreaCode_c20230809__20230809_zbZtWB01dSzk"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:CityAreaCode">(615)</ix:nonNumeric></span> <span id="xdx_908_edei--LocalPhoneNumber_c20230809__20230809_z7Sfc8JSf9s4"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:LocalPhoneNumber">733-4730</ix:nonNumeric></span></b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_905_edei--EntityInformationFormerLegalOrRegisteredName_c20230809__20230809_zmGfzacrLmK2"><ix:nonNumeric contextRef="AsOf2023-08-09" name="dei:EntityInformationFormerLegalOrRegisteredName">Not
Applicable</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span></span></b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 50%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Former
Name or Former Address, if Changed Since Last Report)</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title
    of each class</span></td>
    <td style="text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Trading
    Symbol(s)</span></td>
    <td style="text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Name
    on exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_edei--Security12bTitle_c20230809__20230809__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValuePerShareMember_zahPhpMnxtng"><ix:nonNumeric contextRef="From2023-08-092023-08-09_custom_CommonStock0.001ParValuePerShareMember" name="dei:Security12bTitle">Common Stock,
    $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_edei--TradingSymbol_c20230809__20230809__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValuePerShareMember_zUljoqaqZNif"><ix:nonNumeric contextRef="From2023-08-092023-08-09_custom_CommonStock0.001ParValuePerShareMember" name="dei:TradingSymbol">HROW</ix:nonNumeric></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_edei--SecurityExchangeName_c20230809__20230809__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValuePerShareMember_zohzxhVnKgNf"><ix:nonNumeric contextRef="From2023-08-092023-08-09_custom_CommonStock0.001ParValuePerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq
    Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_edei--Security12bTitle_c20230809__20230809__us-gaap--StatementClassOfStockAxis__custom--Sec8.625SeniorNotesDue2026Member_zoDyMEv19vaf"><ix:nonNumeric contextRef="From2023-08-092023-08-09_custom_Sec8.625SeniorNotesDue2026Member" name="dei:Security12bTitle">8.625% Senior
    Notes due 2026</ix:nonNumeric></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_edei--TradingSymbol_c20230809__20230809__us-gaap--StatementClassOfStockAxis__custom--Sec8.625SeniorNotesDue2026Member_zj6DJTjFVZY5"><ix:nonNumeric contextRef="From2023-08-092023-08-09_custom_Sec8.625SeniorNotesDue2026Member" name="dei:TradingSymbol">HROWL</ix:nonNumeric></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_edei--SecurityExchangeName_c20230809__20230809__us-gaap--StatementClassOfStockAxis__custom--Sec8.625SeniorNotesDue2026Member_z3TLcMB952K8"><ix:nonNumeric contextRef="From2023-08-092023-08-09_custom_Sec8.625SeniorNotesDue2026Member" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq
    Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_907_edei--Security12bTitle_c20230809__20230809__us-gaap--StatementClassOfStockAxis__custom--Sec11.875SeniorNotesDue2027Member_zOfq8yodl0t4"><ix:nonNumeric contextRef="From2023-08-092023-08-09_custom_Sec11.875SeniorNotesDue2027Member" name="dei:Security12bTitle">11.875% Senior
    Notes due 2027</ix:nonNumeric></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_edei--TradingSymbol_c20230809__20230809__us-gaap--StatementClassOfStockAxis__custom--Sec11.875SeniorNotesDue2027Member_zRlXfNsj07T2"><ix:nonNumeric contextRef="From2023-08-092023-08-09_custom_Sec11.875SeniorNotesDue2027Member" name="dei:TradingSymbol">HROWM</ix:nonNumeric></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_edei--SecurityExchangeName_c20230809__20230809__us-gaap--StatementClassOfStockAxis__custom--Sec11.875SeniorNotesDue2027Member_zz4DDzejjvd1"><ix:nonNumeric contextRef="From2023-08-092023-08-09_custom_Sec11.875SeniorNotesDue2027Member" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq
    Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_904_edei--WrittenCommunications_c20230809__20230809_zj4Dm4I40Pk3"><ix:nonNumeric contextRef="AsOf2023-08-09" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Written communications pursuant to Rule
    425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_edei--SolicitingMaterial_c20230809__20230809_zQ9cNyOcdTHd"><ix:nonNumeric contextRef="AsOf2023-08-09" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Soliciting material pursuant to Rule
    14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20230809__20230809_zQCooGunh00b"><ix:nonNumeric contextRef="AsOf2023-08-09" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pre-commencement communications pursuant
    to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20230809__20230809_z1U37EpZoEx2"><ix:nonNumeric contextRef="AsOf2023-08-09" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pre-commencement communications pursuant
    to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Act of 1934: Emerging growth company <span id="xdx_900_edei--EntityEmergingGrowthCompany_c20230809__20230809_zAcDQv59yEg5"><ix:nonNumeric contextRef="AsOf2023-08-09" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Item
2.02 Results of Operations and Financial Condition.</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span>On
August 9, 2023, Harrow Health, Inc. (the &#8220;Company&#8221;) issued a press release and a letter to stockholders announcing its financial
results for the period ended June 30, 2023 and an update on recent corporate events. The press release and letter to stockholders are
being furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.</span></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
information furnished under this Item 2.02 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed
to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;),
or otherwise subject to the liabilities of that Section. The information in this Item 2.02, including Exhibits 99.1 and 99.2, shall not
be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the
extent it is specifically incorporated by reference but regardless of any general incorporation language in such filing.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; background-color: white; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
information furnished under this Item 2.02 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed
to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that such information
or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not assume any obligation
to update such information or exhibit in the future.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Item
9.01. Financial Statements and Exhibits</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(d)</b></span></td>
    <td style="width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">99.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release issued by Harrow
    Health, Inc. on August 9, 2023</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">99.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><a href="ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter to Stockholders by Harrow Health, Inc. dated August 9, 2023</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">104</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the
    Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-indent: 0.5in; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>SIGNATURES</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18.35pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18.35pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>HARROW HEALTH, INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Dated: August 9, 2023</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>/s/
    Andrew R. Boll</i></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Name:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Andrew R. Boll</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18.35pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></p>

<p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kU1OwzAQRk/QO4wi2FXBNvSH7CBAhWirqKkqtiaZgtXEE9lOoUfiljgOFQtaayTLmu/NG8lRNIxm9KQqNPB6v5rDGuumkg5hhVs0qAv0ifT5JQF/r/BdWWekduF5BFPyDHpmFPNb6RshulcWywTY9MqXuAY2Sm4EZIto0PVT0ltVonZKViB1CZmhxih00hz6CWv5RZrqQ1Bt0FhFOgEes779DYJxAUvay08yOwvzeRoNhuEMopmhtuk0rXVUw2OFtXfZHv2rsEoRMkmOBefxdDLKUSsyS3JoH1oUTEwWWL+h8VHOhLfe/a7Qxy+hByAQULYIHXPaMI3H4r9gfEYQ0qfnj0/M9/9Qk84dFTsWM8YzaTayajFDk39Ig2csPQaBG8JFQKGRBvYdDI3/YdvhR+MPFs6g5Q== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><SUB>EXHIBIT
99.1</SUB></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><SUB>&nbsp;</SUB></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><SUB></SUB></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><SUB><IMG SRC="ex99-1_001.jpg" ALT=""></SUB></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><SUB>&nbsp;</SUB></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Harrow
Announces Second Quarter 2023 Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
Quarter 2023 and Recent Selected Highlights:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: -9pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Record
    revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million
    in the sequential quarter.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP
    net loss of ($4.2) million.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Record
    adjusted EBITDA of $11.0 million, an increase of 144% over $4.5 million in the prior-year quarter and an increase of 108% over $5.3
    million in the sequential quarter.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
    public offering of common stock for aggregate gross proceeds of $69 million.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expanded
    Oaktree Loan from $100 million to $112.50 million.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    certain commercial rights to FLAREX&reg;, NATACYN&reg;, TOBRADEX&reg; ST, VERKAZIA&reg;, ZERVIATE&reg;, and Non-Prescription Brands
    FRESHKOTE&reg; and Cationorm&reg; PLUS.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    North American commercial rights to VEVYE&reg;, a novel FDA-approved drug labeled to treat both the signs and symptoms of dry eye
    disease. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
    transfer of New Drug Application for VIGAMOX&reg;.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASHVILLE,
Tenn., August 9, 2023 &ndash; Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the second
quarter and six months ended June 30, 2023. The Company also posted its second quarter <U>Letter to Stockholders</U> and <U>corporate
presentation</U> to the &ldquo;Investors&rdquo; section of its website, <U>harrow.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Our
team has made great progress positioning Harrow as a top-tier U.S.-focused ophthalmic pharmaceutical company,&rdquo; said Mark L. Baum,
CEO of Harrow. &ldquo;Since January of 2023, through a series of transactions, we have not only improved Harrow&rsquo;s balance sheet,
but we&rsquo;ve dramatically improved Harrow&rsquo;s product portfolio, which is now one of the most comprehensive ophthalmic pharmaceutical
offerings in the U.S. market. With what we now have in our &ldquo;bag&rdquo; and continued execution and operational performance by the
Harrow team, we believe we are on our way to achieving the highest financial goals for Harrow&rsquo;s stockholders.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
quarter 2023 figures of merit:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
                                            the Three Months Ended</B></FONT></P>
                                                                                <P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June
                                            30,</B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Six Months Ended<BR> June 30,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    revenues</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,470,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,323,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59,573,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,443,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    margin</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
    gross margin<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,229,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,239,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,872,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,677,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
    net (loss) income<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(494,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">254,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,536,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">967,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted
    EBITDA<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,005,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,505,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,347,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,445,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    net loss per share</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.36</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.32</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
    net loss per share</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.36</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.32</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
    basic net (loss) income per share<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.02</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
    diluted net (loss) income per share<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.02</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
    gross margin, core net (loss) income, core basic and diluted net (loss) income per share (collectively, &ldquo;Core Results&rdquo;),
    and Adjusted EBITDA are non-GAAP measures. For additional information, including a reconciliation of such Core Results and Adjusted
    EBITDA to the most directly comparable measures presented in accordance with GAAP, see the explanation of non-GAAP measures and reconciliation
    tables in the financial tables section.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-MORE-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Announces Second Quarter 2023 Financial Results</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
9, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conference
Call and Webcast</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s management team will host a conference call and live webcast today at 4:45 p.m. Eastern Time to discuss the second quarter
2023 results and provide a business update. To participate in the call, see details below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conference
    Call Details:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wednesday,
    August 9, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4:45
    p.m. Eastern time</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant
    Dial-in:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-833-953-2434
                                            (U.S.)</FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-412-317-5763
                                            (International)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Replay
                                            Dial-in (Passcode 3750229):</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(telephonic
    replay through August 16, 2023)</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-877-344-7529
                                            (U.S.)</FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-412-317-0088
                                            (International)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Webcast:
    <I>(online replay through August 9, 2024)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>harrow.com</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Harrow</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization
of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight
by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions
of Americans each year. For more information about Harrow, please visit <U>harrow.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains &ldquo;forward-looking statements&rdquo; within the meaning of the U.S. Private Securities Litigation Reform Act
of 1995. Any statements in this release that are not historical facts may be considered such &ldquo;forward-looking statements.&rdquo;
Forward-looking statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties
that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations;
our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations
in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing
necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize
the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical
companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges;
regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general;
physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and
additional risks and uncertainties are more fully described in Harrow&rsquo;s filings with the Securities and Exchange Commission, including
its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC&rsquo;s web
site at <U>sec.gov</U>. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made.
Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events,
or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jamie
Webb, Director of Communications and Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>jwebb@harrowinc.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">615-733-4737</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-MORE-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Announces Second Quarter 2023 Financial Results</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
9, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HARROW
HEALTH, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30, </B></FONT></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><P STYLE="margin-top: 0; margin-bottom: 0">December 31,</P>
                                                                  <P STYLE="margin-top: 0; margin-bottom: 0">2022</P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-style: italic">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-style: italic">(unaudited)</TD><TD STYLE="text-align: center; font-style: italic">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">22,754,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">96,270,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">All other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37,542,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,990,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Total current assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">60,296,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">118,260,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">All other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">163,693,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">39,118,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt; font-weight: bold; text-align: left">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">223,989,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">157,378,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">23,011,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">18,632,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loans payable, net of current portion and unamortized debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169,712,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,174,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">All other liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,214,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,332,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">TOTAL LIABILITIES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">201,937,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">130,138,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; font-weight: bold; text-align: left">TOTAL STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">22,052,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">27,240,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt; font-weight: bold; text-align: left">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">223,989,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">157,378,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-MORE-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Announces Second Quarter 2023 Financial Results</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
9, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HARROW
HEALTH, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">For the Three Months Ended</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">June 30,</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">Total revenues</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">33,470,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">23,323,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">59,573,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">45,443,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Cost of sales</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,534,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,271,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,497,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Gross profit</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">23,470,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">16,789,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">41,302,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">32,946,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Selling, general and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,957,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,185,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,845,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,583,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,161,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">914,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,895,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,572,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21,118,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">15,099,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">37,740,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">29,155,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Income from operations</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,352,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,690,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,562,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,791,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total other expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,596,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,889,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,737,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,428,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income tax benefit (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">303,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
                                            loss attributable to </B></FONT><B>Harrow Health, Inc.</B></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,229,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(6,239,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,872,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(8,677,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per share of common stock, basic and diluted</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.32</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-MORE-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Announces Second Quarter 2023 Financial Results</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
9, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HARROW
HEALTH, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the Six Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,</B></FONT></P> </DIV></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash (used in) provided by:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">Operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(3,648,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">5,827,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,219,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(669,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">62,351,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(887,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net change in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(73,516,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,271,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of the period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">96,270,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">42,167,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of the period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,754,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">46,438,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-MORE-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Announces Second Quarter 2023 Financial Results</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
9, 2023</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP
Financial Measures</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Company&rsquo;s results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP),
which are presented and discussed above, management also utilizes Adjusted EBITDA and Core Results, unaudited financial measures that
are not calculated in accordance with GAAP, to evaluate the Company&rsquo;s financial results and performance and to plan and forecast
future periods. Adjusted EBITDA and Core Results are considered &ldquo;non-GAAP&rdquo; financial measures within the meaning of Regulation
G promulgated by the SEC. Management believes that these non-GAAP financial measures reflect an additional way of viewing aspects of
the Company&rsquo;s operations that, when viewed with GAAP results, provide a more complete understanding of the Company&rsquo;s results
of operations and the factors and trends affecting its business. Management believes Adjusted EBITDA and Core Results provide meaningful
supplemental information regarding the Company&rsquo;s performance because (i) they allow for greater transparency with respect to key
metrics used by management in its financial and operational decision-making; (ii) they exclude the impact of non-cash or, when specified,
non-recurring items that are not directly attributable to the Company&rsquo;s core operating performance and that may obscure trends
in the Company&rsquo;s core operating performance; and (iii) they are used by institutional investors and the analyst community to help
analyze the Company&rsquo;s results. However, Adjusted EBITDA, Core Results, and any other non-GAAP financial measures should be considered
as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further,
non-GAAP financial measures used by the Company and the way they are calculated may differ from the non-GAAP financial measures or the
calculations of the same non-GAAP financial measures used by other companies, including the Company&rsquo;s competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted
EBITDA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defines Adjusted EBITDA as net (loss) income, excluding the effects of stock-based compensation and expenses, interest, taxes,
depreciation, amortization, investment (loss) income, net, and, if any and when specified, other non-recurring income or expense items.
Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net (loss) income. Adjusted EBITDA
has limitations and should not be considered as an alternative to gross profit or net (loss) income as a measure of operating performance
or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-MORE-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Announces Second Quarter 2023 Financial Results</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
9, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net loss, for the three months
and six months ended June 30, 2023, and for the same periods in 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HARROW
                                            HEALTH, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECONCILIATION
OF NET LOSS TO ADJUSTED EBITDA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">For the Three Months Ended</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">June 30,</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">GAAP net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(4,229,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(6,239,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(10,872,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(8,677,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,412,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,993,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,045,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,009,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,704,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,794,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,451,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,586,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Income tax expense (benefit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(303,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">424,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">690,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">843,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,843,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,050,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">802,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Investment loss (income), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">714,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,095,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,328,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,842,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other expense, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">178,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,614,000</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Adjusted EBITDA</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">11,005,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,505,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16,347,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,445,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    $5,465,000 for the loss on extinguishment of debt.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
Results</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Harrow
Core Results, including core gross margin, core net income (loss), core operating income, core basic and </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">diluted
income (loss) per share, and core operating margin, exclude all amortization and impairment charges of intangible assets, excluding software
development costs, net gains and losses on investments and equity securities, including equity method gains and losses and equity valued
at fair value through profit and loss (&ldquo;FVPL&rdquo;), preferred stock dividends, and gains/losses on forgiveness of debt. In other
periods, Core Results may also exclude fair value adjustments of financial assets in the form of options to acquire a company carried
at FVPL, obligations related to product recalls, certain acquisition-related items, restructuring charges/releases and associated items,
related legal items, gains/losses on early extinguishment of debt or debt modifications, impairments of property, plant and equipment
and software, as well as income and expense items that management deems exceptional and that are or are expected to accumulate within
the year to be over a $100,000 threshold.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a reconciliation of Core Results, non-GAAP measures, to the most comparable GAAP measures for the three and six months ended
June 30, 2023, and for the same periods in 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Three Months Ended June 30, 2023</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GAAP</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amortization of Certain Intangible Assets</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gains</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other </B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Items</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Core</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Gross profit</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">23,470,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,649,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">26,119,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross margin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,352,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,843,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,195,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Loss) income before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,244,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,843,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">714,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(509,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,229,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,843,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">714,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(494,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted loss per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.02</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted average number of shares of common stock outstanding, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,458,677</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,458,677</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-MORE-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Announces Second Quarter 2023 Financial Results</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
9, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Six Months Ended June 30, 2023</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GAAP</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amortization of Certain Intangible Assets</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Losses</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other </B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Items</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Core</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Gross profit</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">41,302,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,694,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">45,996,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross margin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,562,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,050,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,612,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Loss) income before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,175,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,050,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,328,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,614,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,839,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">303,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">303,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,872,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,050,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,328,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,614,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,536,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted loss per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.36</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.05</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted average number of shares of common stock outstanding, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,379,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,379,354</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Three Months Ended June 30, 2022</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GAAP</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amortization of Certain Intangible</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assets</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gains</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Core</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">Gross profit</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">16,789,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">341,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">17,130,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross margin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,690,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,088,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Loss) income before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,199,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,095,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">294,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,239,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,095,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">254,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic (loss) earnings per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.23</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted (loss) earnings per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.23</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average number of shares of common stock outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Basic </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,303,458</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,303,458</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,303,458</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,234,177</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Six Months Ended June 30, 2022</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GAAP</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amortization of Certain Intangible</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assets</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gains</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Core</B></FONT></P> <P STYLE="text-align: center; padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">Gross profit</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">32,946,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">682,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">33,628,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross margin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,791,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">802,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,593,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Loss) Income before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,637,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">802,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,842,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,007,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,677,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">802,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,842,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">967,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic (loss) earnings per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.32</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.04</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted (loss) earnings per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.32</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average number of shares of common stock outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Basic </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,265,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,265,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,265,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,270,639</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
    basic and diluted (loss) earnings per share is calculated using the weighted-average number of shares of common stock outstanding
    during the period. Core basic and diluted (loss) earnings per share also contemplates dilutive shares associated with equity-based
    awards as described in Note 2 and elsewhere in the Condensed Consolidated Financial Statements included in the Company&rsquo;s Quarterly
    Report on Form 10-Q for the quarter ended June 30, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-END-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
99.2</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-2_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Letter
to Stockholders</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
9, 2023</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Harrow Stockholders:</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
am pleased to report second quarter 2023 <B>record revenues</B> of $33.5 million and <B>record adjusted EBITDA </B>of $11.0 million.
Notably, we also reported the largest sequential quarterly increase in revenues and adjusted EBITDA in Harrow&rsquo;s history &ndash;
from the first to second quarters of 2023. Recall that in my <I>May 11, 2023, Stockholder Letter</I>, I wrote that Harrow had &ldquo;entered
a new revenue paradigm,&rdquo; a notion that I believe is supported by these figures.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
a difference a few months makes. When I last corresponded with you, we were focused behind the scenes on completing three transactions
that I believed would give Harrow the best opportunity to achieve the highest financial goals of Harrow&rsquo;s Five-Year Strategic
Plan, which we initiated in January of this year. These three transactions, all of which closed at the beginning of the third quarter,
were: (1) the acquisition of substantially all products in the North American Santen ophthalmic pharmaceutical portfolio; (2) the acquisition
from Novaliq of the North American rights to VEVYE&reg;, a novel FDA-approved drug labeled to treat both the signs and symptoms of dry
eye disease (DED); and (3) the strengthening of our balance sheet through a pair of financings, including a well-executed equity financing
and the expansion of our Oaktree Capital facility.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Today,
the Harrow ophthalmic pharmaceutical portfolio is more potent than ever. We can now more broadly and comprehensively deliver important
clinical value to our customers. For Harrow&rsquo;s stockholders, I believe this more robust product portfolio should cause (a) annual
revenue growth for many years to come and (b) consolidated quarterly gross margins to begin to float higher this year.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the balance of this Stockholder Letter, in addition to adding color to our second quarter 2023 performance, I intend to describe what
you, as my &ldquo;business partners,&rdquo; should expect during the balance of this Five-Year Strategic Plan period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
I go any further, let me answer the question one might logically ask after reading the second paragraph above: &ldquo;What are the &lsquo;highest
financial goals&rsquo; of our Five-Year Strategic Plan?&rdquo;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Simply
put, we believe that &ndash; with our current product portfolio and continued strategic execution by the Harrow team &ndash; we can become
a top-tier U.S.-focused ophthalmic pharmaceutical company capable of producing annual revenues of $1 billion or more &ndash; at very
attractive operating margins.</I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recognizing
that our Five-Year Strategic Plan consists of a series of One-Year Plans, based on our results to date, we remain confident in our 2023
financial guidance of $135 million to $143 million in net revenues and $44 million to $50 million in adjusted EBITDA. </I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Regarding
our 2023 financial guidance, we intend to provide an update to our financial guidance later in the year after we have a few months of
operations under our belt with our new product portfolio.</I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Second
Quarter 2023 Financial Overview</U></I></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Link
</U>to Selected GAAP Operating Results.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Link
</U>to Selected Core Results (a Non-GAAP Measure).</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Record
revenues of $33.5 million for the second quarter of 2023 represent a 44% increase over the prior-year&rsquo;s second quarter revenues
of $23.3 million.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted
EBITDA increased 144% to $11.0 million for the second quarter of 2023 compared with Adjusted EBITDA of $4.5 million during the same period
last year, primarily because of increased revenues of our branded products. Core net loss was ($494,000) for the second quarter of 2023
compared with core net income of $254,000 for the second quarter of 2022.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had $22.8 million in cash and cash equivalents at the end of the second quarter. Subsequently, our cash balance changed dramatically
because of the closing of a $69 million offering of our common stock and a $12.5 million drawdown from our expanded Oaktree Capital loan.
We used a portion of the proceeds from these two financings to fund initial payments associated with our acquisitions of VEVYE
and the products from Santen.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the second quarter, Harrow completed the transfer of new drug applications (NDAs) for ILEVRO&reg;, NEVANAC&reg;, and MAXIDEX&reg;. Harrow
received net profit transfers on these products during April, but upon NDA transfers in early May, we began booking full revenues from
those product sales. Harrow received net profit transfers for VIGAMOX&reg; throughout the second quarter and recently announced the completion
of that NDA transfer and began commercialization of VIGAMOX.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also officially launched IHEEZO&reg; in May of this year at the American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
in San Diego.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
gross margin improved 500 basis points to 78% in the second quarter of 2023 compared with core gross margin of 73% in the second quarter
of 2022.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general, and administrative (SG&amp;A) expenses for the second quarter of 2023 increased to $20.0 million compared with $14.2 million
during the same period last year. The year-over-year increase is due in large part to an expansion of our general operating and sales
infrastructure to support our branded product acquisitions and launches in 2023, coupled with an increase in stock-based compensation
of over $3 million largely associated with management performance stock units (or PSUs) that have vesting terms based on achievement
of Harrow common stock price targets of $25 to $50.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development (R&amp;D) costs were $1.2 million in the second quarter of 2023 compared with $914,000 during the same period last year.
Throughout the remainder of 2023 and next year, R&amp;D costs should creep up as we expand our medical and clinical affairs capabilities
and gain steam on some of the tech transfer manufacturing processes for our recent product acquisitions.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP
operating income was $2.4 million for the second quarter of 2023 compared with GAAP operating income of $1.7 million during the same
period last year.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
diluted net loss per share for the second quarter of 2023 was ($0.02) compared with core diluted net income per share of $0.01 during
the same period last year.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of all non-GAAP financial measures in this letter begins on page 11.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>GAAP
Operating Results</U></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected
financial highlights regarding GAAP operating results for the three months and six months ended June 30, 2023, and for the same periods
in 2022 are as follows:</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">For the Three Months Ended</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">June 30,</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the Six Months Ended </B></FONT></P> <P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,</B></FONT></P> </DIV></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">Total revenues</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">33,470,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">23,323,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">59,573,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">45,443,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cost of sales</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,534,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,271,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,497,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Gross profit</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">23,470,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">16,789,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">41,302,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">32,946,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Selling, general and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,957,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,185,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,845,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,583,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,161,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">914,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,895,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,572,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21,118,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">15,099,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">37,740,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">29,155,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Income from operations</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,352,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,690,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,562,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,791,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total other expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,596,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,889,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,737,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,428,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Income tax benefit (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">303,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
loss attributable to Harrow Health, Inc. </B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,229,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(6,239,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,872,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(8,677,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Net loss per share of common stock, basic and diluted</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.32</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Core
Results (a Non-GAAP Measure)</U></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
Results (non-GAAP measures), which we define as the after-tax earnings and other operational and financial metrics generated from our
principal business, for the three months and six months ended June 30, 2023, and for the same periods in 2022, are as follows:</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">For the Three Months Ended</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">June 30,</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the Six Months Ended </B></FONT></P> <P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,</B></FONT></P> </DIV></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">Net revenues</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">33,470,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">23,323,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">59,573,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">45,443,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross margin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core gross margin<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,229,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,239,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,872,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,677,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core net (loss) income<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(494,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">254,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,536,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">967,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted EBITDA<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,005,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,505,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,347,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,445,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Basic net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.23</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.36</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.32</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Diluted net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.23</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.36</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.32</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core basic net (loss) income per share<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.02</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.05</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.04</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core diluted net (loss) income per share<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.02</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.05</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
    gross margin, core net (loss) income, core basic and diluted net (loss) income per share (collectively, &ldquo;Core Results&rdquo;),
    and Adjusted EBITDA are non-GAAP measures. For additional information, including a reconciliation of such Core Results and Adjusted
    EBITDA to the most directly comparable measures presented in accordance with GAAP, see the explanation of non-GAAP measures and reconciliation
    tables <U>at the end</U> of this Letter to Stockholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Revenue
Buckets&rdquo;</I></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
achieve a billion dollars in annual revenue during this Five-Year Strategic Planning cycle, Harrow must generate significant sales from
what I internally refer to as our <I>&ldquo;Revenue Buckets.&rdquo;</I> As a result of the recently announced acquisitions, we believe
we now have five (5) discreet Revenue Buckets with nine-figure annual revenue potential. We believe sales from products in these
Revenue Buckets, in the aggregate, have the potential to achieve the &ldquo;highest financial goals&rdquo; I referred to on page 1 of
this Stockholder Letter.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
Revenue Buckets consist of a single product and others contain groups of products. I believe IHEEZO and VEVYE are our largest revenue
opportunities &ndash; <I>without question</I>. That said, they are also new sources of revenue, with IHEEZO only launching a few months
ago and VEVYE expected to launch later in the year. Regardless of the exact timing of the start and steady build of revenue flow from
these two exciting products, the key is that (a) Harrow now has them both, and (b) we have an incredibly strong conviction of market
need and, ultimately, market acceptance of both products.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Here
is a more detailed description of the five Revenue Buckets:</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Bucket
1</U>: IHEEZO&reg;</I></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
our team began market research on IHEEZO, some advisors said, &ldquo;<I>I really don&rsquo;t think I need this product because what I
am doing for ocular anesthesia is okay</I>.&rdquo; When we pressed about what their respective ocular anesthesia protocols consisted
of, our belief in the future success of IHEEZO gained strength. Responses from these advisors included myriad protocols, with most using
multiple different anesthetics during a series of applications &ndash; all with inconsistent durations of anesthetic effect. Inconsistent
anesthetic durability or reliability isn&rsquo;t good for the doctor and surely isn&rsquo;t good for the patient! Discussions about the
importance of an anesthetic caused many of our advisors to realize there was an opportunity for a more reliable ocular anesthetic and
one that could create practice efficiencies.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast-forward
to the initial phase of the IHEEZO launch and the anecdotal reports we&rsquo;ve received from IHEEZO users. With IHEEZO, they can use
a single product for ocular anesthesia. The onset and duration of the anesthetic effect are consistent and predictable. Ophthalmologists
like the viscosity of the IHEEZO gel, which is 75% less viscous than the leading branded lidocaine-based gel anesthetic. Staff at ambulatory surgery centers (ASCs) and hospitals appreciate the compliance benefits of our single-use packaging. And while it&rsquo;s
early in the launch, when we see a growing list of accounts trial IHEEZO, use samples, order it, use those units, and re-order more,
our confidence that we have a winning product grows.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
way to explain what we see among IHEEZO users is to draw an analogy to how I felt about my Blackberry cell phone 15 years ago. Similar
to how our advisors described their ocular anesthesia protocols during our market research phase as &ldquo;good,&rdquo; I would have
said the utility of my Blackberry was &ldquo;good,&rdquo; with features like texting, a decent camera, and reliable email access. If
approached to switch to the iPhone, I would have said that my Blackberry was &ldquo;good&rdquo; and that I didn&rsquo;t need the iPhone.
Of course, once I experienced the value and benefits of an iPhone, I never went back to a Blackberry. In turn, we
believe eyecare professionals (ECPs) who implement IHEEZO into their ocular anesthesia protocols and experience IHEEZO&rsquo;s benefits
won&rsquo;t return to their old, and perhaps less efficient, ways.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
math on the IHEEZO market opportunity is straightforward. We believe there are two main anesthetic use cases: (1) a surgical intervention
such as cataract, glaucoma, and retina procedures, which takes place in a hospital or outpatient setting of care, and (2) an intervention
in a physician&rsquo;s office, such as an intravitreal injection. We estimate that, in the aggregate, there are more than 12 million
such use cases in the U.S. each year. We were granted a product-specific J-Code (J2403) for all such use cases, and the current wholesale
acquisition cost (or WAC) is $544 per unit.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
reimbursement for the IHEEZO J-Code:</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ability for an ASC, for example, to bill using J2403 is <I>temporary</I> and will only last for about three years. After this time,
    we may petition the authorities at the Centers for Medicare &amp; Medicaid Services (CMS) to extend, annually, what is referred to
    as &ldquo;pass-through payment&rdquo; (or payment outside of the capitated fee ASCs are paid for completing a cataract surgery).
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    successfully petition CMS for a pass-through payment extension, we must demonstrate that IHEEZO reduces reliance on opioids. We intend
    to present such data to CMS <U>before</U> our temporary pass-through period ends. If CMS approves our request for a pass-through
    payment extension, ASCs can utilize J2403 until CMS changes its policy, in general, or specifically, towards IHEEZO. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    the other hand, the &ldquo;billability&rdquo; of J2403 in the physician&rsquo;s office setting of care, for intravitreal injections,
    for example, is <B>not</B> temporary and has no limitation on the duration of use. Importantly, ophthalmologists and their staff,
    in this setting of care, are very familiar with &ldquo;buy and bill&rdquo; products like IHEEZO, perhaps easing the process for IHEEZO
    adoption. </FONT></TD></TR>
  </TABLE>
<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the number of use cases for the physician&rsquo;s office setting of care is double that of the ASC/hospital, creating a
multi-billion-dollar annual revenue opportunity for IHEEZO. Therefore, the physician&rsquo;s office setting of care is our primary market
for IHEEZO, and the ASC and hospital market is secondary.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are not going to win all the potential business for IHEEZO in either setting of care, given the overall size of the opportunity, even
if we eventually achieve a blended market share for IHEEZO close to what we have achieved in, for example, the perioperative cataract
surgery market with our ImprimisRx compounded pharmaceutical formulations (i.e., touching an estimated 20% of the total number of U.S.
cataract surgeries), IHEEZO will have been a great success! Related to this point, our 2023 financial guidance was conservative and did
not include much IHEEZO revenue; however, we expect to see quarterly revenue for IHEEZO build sequentially and for each annual period
going forward.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
being in the initial phase of our IHEEZO launch, feedback from early adopters has been positive, with indications from users that there
may be more potential applications for IHEEZO than we had originally anticipated (e.g., glaucoma and retina surgeries and certain
laser procedures). Also, we always hoped IHEEZO would help address the opioid crisis in our country, and we have been thrilled to hear
from several surgeons that, with IHEEZO, as was the case in the IHEEZO clinical studies, they, too, were able to eliminate opioid use
from most of their cataract surgeries. If we can make even a small impact on the opioid crisis, it would be fantastic for patients and
our ophthalmologist-customer&rsquo;s practice. Finally, we are seeing wins in our market access efforts to get IHEEZO on commercial formularies.
And, as we hoped, <I>IHEEZO is reimbursed in all labeled care settings.</I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Bucket
2</U>: Dry Eye Disease and Other Ocular Surface Conditions</I></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
the end of this year, we intend to launch VEVYE as our cornerstone product in the U.S. DED space. The U.S. dry eye market is large and
growing, with an estimated diagnosed patient population that exceeds 16 million, 9 million of whom are diagnosed with moderate to severe
disease. The DED market is a therapeutic area we know well and a patient population we have meticulously studied and served for many
years through our ImprimisRx brand, dispensing ImprimisRx compounded formulations to more than 6,000 U.S. prescribers to help these ECPs
manage their patients&rsquo; dry eye conditions.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
a handful of prescription products being available and myriad over-the-counter (OTC) choices, <I>the data is unmistakable &ndash; American
DED patients are highly underserved by these choices</I> (i.e., 92% are un- or under-treated due to limited efficacy and poor tolerability
in current prescription product options<SUP>i</SUP>). We believe that a part of the reason fewer than 10% of the diagnosed DED patient
population uses a prescription DED therapy has to do with the performance and tolerability profiles of the existing prescription product
choices &ndash; <I>which,</I><I> despite their shortcomings, in the aggregate, deliver north of $1 billion in annual sales</I>.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the existing prescription drug choices have been suboptimal for many years, we view the U.S. DED market as <I><U>wide open</U></I> and
intend to compete vigorously to ensure patients have access to VEVYE. We won&rsquo;t win every DED prescription; however, with so many
U.S. DED patients who have tried and failed one or more of the existing prescription choices and a large percentage of patients who have
never treated their disease with a prescription product, we believe there is a very significant need and opportunity for a DED medication
that shows efficacy within one month, has a lasting treatment effect, and doesn&rsquo;t cause pain, eye or nose irritation, sneezing,
or dysgeusia upon instillation. We believe VEVYE will meet this need, win meaningful market share, and expand the pool of patients benefitting
from a prescription DED therapy.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
believe prescribers will appreciate the data supporting VEVYE. The core of VEVYE is the water-free EyeSol&reg; technology, which our
partner Novaliq developed. In my view, what Novaliq has done with EyeSol is to essentially  reinvent &ldquo;the eyedrop.&rdquo;
Because of VEVYE&rsquo;s patented EyeSol technology, patients will experience exceptional comfort (i.e., over 99.8% of patients dosed
in VEVYE&rsquo;s clinical development program experienced no or mild instillation site pain). But the promise of VEVYE is also rapid
clinical onset (29 days) and continued improvement of both signs and symptoms over 56 weeks. Dosing frequency also matters, and VEVYE
is the only twice-daily cyclosporine-based product indicated for both signs and symptoms of DED. VEVYE contains no water, pH, or osmolarity;
it has a totally unique feel when applied to the eye&rsquo;s surface. I can&rsquo;t wait to hear the responses from patients when they
administer VEVYE, a light-feeling and small (10 microliter) drop. <I>There&rsquo;s just nothing else like VEVYE on the market.</I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospect of providing a product like VEVYE to a patient population in such great need is a motivating factor as we begin our VEVYE market
access and pricing analysis work!</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjacent
ocular surface disease products we recently acquired from Santen will further bolster the toolkit we intend to provide to ECPs, including
such well-known products as:</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FLAREX&reg;,
    the only branded steroid indicated for ocular surface inflammation, provides the opportunity to treat inflammation associated with
    a wide range of ocular surface conditions (including DED<SUP>ii</SUP>).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOBRADEX&reg;
    ST, a corticosteroid and antibacterial combination eye drop, has shown a &gt;50% reduction in symptoms commonly associated with blepharitis/blepharoconjunctivitis<SUP>iii</SUP>.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FRESHKOTE&reg;,
an OTC, preservative-free lubricant for dry eye.</FONT></TD></TR>
  </TABLE>
<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in">We
are currently working to transfer the marketing authorizations (MAs) for FLAREX, TOBRADEX ST, and FRESHKOTE to the Harrow platform, and
we expect that, as the MAs transfer over the coming months, these products will be immediately accretive to Harrow&rsquo;s earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(i)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source: OIS Dry Eye Conference (March 2021)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(ii)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Charters L. Ocular surface inflammation: vicious
    cycle of ocular surface disruption. Ophthalmology Times. October 16, 2019. Accessed May 19, 2021. <U>https://www.ophthalmologytimes.com/view/ocular-surface-inflammation-vicious-cycle-ocular-surface-disruption.</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(iii)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randomized, investigator-masked, active-controlled, parallel-group trial conducted at seven private practice clinical sites in the United States with 122 adult patients who had moderate to severe blepharitis/blepharoconjunctivitis.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Bucket
3</U>: TRIESENCE&reg;</I></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our announcement of our agreement to purchase TRIESENCE, we have consistently heard from ECPs throughout the U.S., especially retina-focused
surgeons, about their desire, need, and excitement about having TRIESENCE, <I>which has been in and out of stock for several years</I>,
back in stock and available. During this out-of-stock situation, ECPs have had to resort to off-label and potentially dangerous manipulation
of other products, which cannot be billed using the TRIESENCE product-specific J-Code (J3300). We expect this all to change by the end
of the year and that in the first half of 2024, TRIESENCE should be again available in the U.S. market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRIESENCE
has a unique label as it is approved for (1) visualization of the vitrectomy and (2) the treatment of the following ophthalmic diseases:
sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. We estimate
there are approximately 600,000 annual use cases for TRIESENCE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Like
hundreds of critical medicines in the U.S., TRIESENCE has been listed on the FDA&rsquo;s drug shortage list for much of the past five
years. While several factors have contributed to this, pricing has challenged the economic incentive to ensure the widespread availability
of TRIESENCE. In fact, TRIESENCE has not seen any upward pricing adjustment in about <I>12 years &ndash; not even to keep up with inflation</I>.
I suspect few products in the U.S. ophthalmic pharmaceutical market have had complete pricing stasis for that long. While it may sound
great to keep the price of TRIESENCE stable for 12 years, the costs associated with producing this critical medicine have increased markedly
during this period. To avoid any disincentive in making TRIESENCE available and to best ensure TRIESENCE is finally off the FDA&rsquo;s
drug shortage list, once we have access to the TRIESENCE NDA, we intend to adjust, in a reasonable way, TRIESENCE pricing to reflect
the value it delivers &ndash; while at the same time, investing significantly in inventory build to meet the demand that we expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the prospects of achieving a TRIESENCE inventory build, despite TRIESENCE being a tricky product to manufacture, we (along with our contracted
manufacturing partner) are making solid progress. Recently, demo batches of TRIESENCE were successfully completed, and this October,
we expect to have results from the first-of-three process performance qualification (or PPQ) batches. Assuming analytical results from
that PPQ batch are consistent with the demo batches, we should be positioned to have TRIESENCE in inventory during the first half of
2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Bucket
4</U>: Specialty Anterior Segment (SAS)</I></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is an important and steady source of revenue because each product below has a very high need and utility among eyecare professionals.
Additionally, when we consider each product&rsquo;s unique characteristics (including patents, brand name recognition, and manufacturing
know-how) we see the potential for a durable source of revenue that strategically fits within Harrow&rsquo;s portfolio of front-of-the-eye
or anterior segment products. These products include:</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ILEVRO&reg;
    and NEVANAC&reg;, patented, non-steroidal, anti-inflammatory eye drops (NSAIDs) indicated for pain and inflammation associated with
    cataract surgery.</FONT></TD></TR>
  </TABLE>
<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    extensive portfolio of antibiotic and steroid products that offer excellent options for infection and inflammation, including:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAXIDEX&reg;,
    a steroid, </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIGAMOX&reg;,
    an antibiotic, </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOBRADEX&reg;
    ST, a patented combination antibiotic and steroid, and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAXITROL&reg;,
    an anti-infective steroid combination.</FONT></TD></TR>
  </TABLE>
<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NATACYN&reg;,
    the only on-label antifungal eye drop.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VERKAZIA&reg;
    (orphan exclusivity until 2028), the only patented topical immunomodulator approved for the treatment of vernal keratoconjunctivitis
    (VKC).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZERVIATE&reg;,
    patented and the only H1 receptor antagonist formulated with Hydrella&reg; lubricating ingredients for the treatment of ocular itching
    with allergic conjunctivitis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IOPIDINE&reg;,
    the gold standard for treating or preventing intraocular pressure during and after YAG laser eye surgery, a procedure that is required
    for an estimated 40% of cataract surgery patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fortisite</U>&reg;
    is a high-concentration, refrigeration-stable, compounded fortified antibiotic available through the ImprimisRx FDA-registered 503B
    facility for in-office use.</FONT></TD></TR>
  </TABLE>
<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Bucket
5</U>: ImprimisRx&rsquo;s Compounded Pharmaceutical Products (CPPs)</I></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
last and certainly not least of these Revenue Buckets is the balance of our ImprimisRx CPP formulations. This business has historically
served Harrow stockholders well by producing double-digit annual revenue growth and consistent streams of cash, which we have invested
to build the entirety of what we now own. The ImprimisRx CPP business has also been an innovation hub, allowing Harrow to develop
new affordable and accessible compounded formulations to address clinical needs that are unmet by FDA-approved drug products.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ImprimisRx&rsquo;s
CPPs have played a vital role in Harrow&rsquo;s mission to help patients manage the preservation of their sight by making drugs accessible
and affordable. Such innovative compounded formulations include preservative- and boric acid-free compounded atropine formulations, available
at <U>atropine.com</U>, which are stable at a biologically comfortable pH and undergo a strict series of validated analytical tests to
ensure consistency, potency, and stability. The market need for CPPs was illustrated in our recent partnership with Elevance Health,
one of the Nation&rsquo;s largest health insurance companies, covering the nine million members of its Blue View Vision<SUP>SM</SUP>
plan. This partnership made ImprimisRx&rsquo;s atropine and Total Tears&reg; ophthalmic formulations available through approximately
36,000 private practice eyecare professionals, local optical stores, and national retail stores. We are confident that Harrow&rsquo;s
10,000<SUP>+</SUP> customer base wants and needs the entirety of the Harrow portfolio, including compounded formulations from ImprimisRx,
the U.S. leader &ndash; <I>by far</I> &ndash; in ophthalmic pharmaceutical compounding.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stockholders should also know that we are always interested in whether an ImprimisRx compounded formulation has the potential to be developed
into an FDA-approved product (as we are in the process of attempting with the MELT-300 program from Melt Pharmaceuticals, noting the
MELT-300 product candidate was inspired by the MKO Melt&reg; formulation, which ImprimisRx currently offers).</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also remain committed to our charity and mission work worldwide by providing ImprimisRx compounded ophthalmic formulations to the noble
physicians who generously donate their time to helping those with limited resources or no access to the ophthalmic care they need. This
continues to serve as a great source of pride for the Harrow Family, including our stockholders.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Closing</U></I></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hope this Stockholder Letter clarifies how we intend to achieve our long-term financial objectives. Some of the various Revenue Bucket
products are more contributory currently than others. For example, IHEEZO is generating sales and ramping up, but VEVYE and TRIESENCE
aren&rsquo;t expected to kick into gear until next year. Regardless of the exact timing of when revenues for a Harrow product begin to
mount or grow, the key for our stockholders is that we now have the products needed to achieve our highest financial objectives. <I>(In
addition, if our former subsidiary Melt Pharmaceuticals is successful in turning MELT-300 into an FDA-approved product during this Five-Year
Strategic Planning cycle, we may be able to add even more revenues to the mix because, aside from our large equity position and royalty
rights on MELT-300, Harrow has a right of first refusal on Melt&rsquo;s commercial rights!)</I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
keep in mind that when we launch a product like IHEEZO or VEVYE, it isn&rsquo;t like Herm&egrave;s running a <I>One-Day Only 50% Off
Sale</I> for Birkin Bags; it takes 18-24 months to develop an effective market access strategy and build sales momentum, even when you
have what we believe are winning products like IHEEZO and VEVYE. (TRIESENCE is a bit different because the market is already so familiar
with the product, there is a permanent TRIESENCE product-specific J-Code, and the demand for TRIESENCE has been building for years as
the product has been in short supply.)</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
also want to admit that it is a &ldquo;lock bet&rdquo; that we will make mistakes executing our Five-Year Strategic Plan. It should also
be assumed that some Revenue Buckets will underperform. On the other hand, we may also have Revenue Buckets that overperform! Success
for Harrow has never been a linear path &ldquo;up and to the right,&rdquo; and I do not expect that to change.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Harrow&rsquo;s CEO, credibility is my primary currency. Perhaps as important as closing our recent transactions is that
this management team was transparent with Harrow shareholders about our belief that we would accomplish these things &ndash; <I>and now
we have</I>. I also believe many readers of this Stockholder Letter would agree that we didn&rsquo;t overpay for our newly acquired products!
We also didn&rsquo;t dilute stockholders unless we had what we felt was a potential &ldquo;whopper&rdquo; of a deal (e.g., the VEVYE
transaction). Finally, we promised that we wouldn&rsquo;t add to our debt unless doing so acquired value which, in the aggregate, was
expected to lower our overall leverage ratios. I believe we delivered on all these promises.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Today,
we have line-of-sight to achieving the highest financial goals of our current Five-Year Strategic Plan, making Harrow a top-tier U.S.-focused
ophthalmic pharmaceutical company. I am more confident today than ever that this will happen. In terms of the future we see for Harrow,
as American lyricist Carolyn Leigh penned and as Frank Sinatra sang, &ldquo;The best is yet to come!&rdquo; <I>I look forward to
updating you again in my next Letter to Stockholders in November of 2023.</I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
L. Baum</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founder,
Chairman of the Board, and Chief Executive Officer</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nashville,
Tennessee</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Index
to Previous Letters to Stockholders</U></B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>4Q 2022</U></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>4Q 2021</U></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>4Q 2020</U></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>4Q 2019</U></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>3Q 2022</U></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>3Q 2021</U></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>3Q 2020</U></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>3Q 2019</U><BR></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>2Q 2022</U></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>2Q 2021</U></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><U>2Q 2020</U></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 19%; text-align: center"><U>1Q23</U></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: center"><U>1Q 2022</U></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: center"><U>1Q 2021</U></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: center"><U>1Q 2020</U></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s
remarks in this stockholder letter include forward-looking statements within the meaning of federal securities laws. Forward-looking
statements are subject to numerous risks and uncertainties, many of which are beyond Harrow&rsquo;s control, including risks and uncertainties
described from time to time in its SEC filings, such as the risks and uncertainties related to the Company&rsquo;s ability to make commercially
available its FDA-approved products and compounded formulations and technologies, and FDA approval of certain drug candidates in a timely
manner or at all.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a list and description of those risks and uncertainties, please see the &ldquo;Risk Factors&rdquo; section of the Company&rsquo;s Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the SEC.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow&rsquo;s
results may differ materially from those projected. Harrow disclaims any intention or obligation to update or revise any financial projections
or forward-looking statements whether because of new information, future events or otherwise. This stockholder letter contains time-sensitive
information and is accurate only as of today.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
Harrow refers to non-GAAP financial measures, specifically Adjusted EBITDA, adjusted earnings, core gross margin, core net income (loss),
and core basic and diluted net income (loss) per share. A reconciliation of non-GAAP measures with the most directly comparable GAAP
measures is included in this letter.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
compounded formulation is FDA-approved. All compounded formulations are customizable. Other than drugs compounded at a registered outsourcing
facility, all compounded formulations require a prescription for an individually identified patient consistent with federal and state
laws.</I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>All
trademarks, service marks, and trade names included or referenced in this publication are the property of their respective owners. </I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-GAAP
Financial Measures</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Company&rsquo;s results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP),
which are presented and discussed above, management also utilizes Adjusted EBITDA and Core Results, unaudited financial measures that
are not calculated in accordance with GAAP, to evaluate the Company&rsquo;s financial results and performance and to plan and forecast
future periods. Adjusted EBITDA and Core Results are considered &ldquo;non-GAAP&rdquo; financial measures within the meaning of Regulation
G promulgated by the SEC. Management believes that these non-GAAP financial measures reflect an additional way of viewing aspects of
the Company&rsquo;s operations that, when viewed with GAAP results, provide a more complete understanding of the Company&rsquo;s results
of operations and the factors and trends affecting its business. Management believes Adjusted EBITDA and Core Results provide meaningful
supplemental information regarding the Company&rsquo;s performance because (i) they allow for greater transparency with respect to key
metrics used by management in its financial and operational decision-making; (ii) they exclude the impact of non-cash or, when specified,
non-recurring items that are not directly attributable to the Company&rsquo;s core operating performance and that may obscure trends
in the Company&rsquo;s core operating performance; and (iii) they are used by institutional investors and the analyst community to help
analyze the Company&rsquo;s results. However, Adjusted EBITDA, Core Results, and any other non-GAAP financial measures should be considered
as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further,
non-GAAP financial measures used by the Company and the way they are calculated may differ from the non-GAAP financial measures or the
calculations of the same non-GAAP financial measures used by other companies, including the Company&rsquo;s competitors.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adjusted
EBITDA</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defines Adjusted EBITDA as net (loss) income, excluding the effects of stock-based compensation and expenses, interest, taxes,
depreciation, amortization, investment (loss) income, net, and, if any and when specified, other non-recurring income or expense items.
Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net (loss) income. Adjusted EBITDA
has limitations and should not be considered as an alternative to gross profit or net (loss) income as a measure of operating performance
or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net loss, for the three months
and six months ended June 30, 2023, and for the same periods in 2022:</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">For the Three Months Ended</P>
                                                                  <P STYLE="margin-top: 0; margin-bottom: 0">June 30,</P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">For the Six Months Ended</P>
                                                                  <P STYLE="margin-top: 0; margin-bottom: 0">June 30,</P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">GAAP net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(4,229,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(6,239,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(10,872,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(8,677,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,412,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,993,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,045,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,009,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,704,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,794,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,451,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,586,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Income tax expense (benefit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(303,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">424,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">690,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">843,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,843,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,050,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">802,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Investment loss (income), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">714,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,095,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,328,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,842,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Other expense, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">178,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;5,614,000 <SUP>(1)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Adjusted EBITDA</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,005,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,505,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,347,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,445,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes $5,465,000 for the loss on extinguishment of debt.</FONT></TD></TR>
</TABLE>


<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Core
Results</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Core Results, including core gross margin, core net income (loss), core operating income, core basic and diluted income (loss) per share,
and core operating margin, exclude all amortization and impairment charges of intangible assets, excluding software development costs,
net gains and losses on investments and equity securities, including equity method gains and losses and equity valued at fair value through
profit and loss (&ldquo;FVPL&rdquo;), preferred stock dividends, and gains/losses on forgiveness of debt. In other periods, Core Results
may also exclude fair value adjustments of financial assets in the form of options to acquire a company carried at FVPL, obligations
related to product recalls, certain acquisition-related items, restructuring charges/releases and associated items, related legal items,
gains/losses on early extinguishment of debt or debt modifications, impairments of property, plant and equipment and software, as well
as income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a
$100,000 threshold.</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a reconciliation of Core Results, non-GAAP measures, to the most comparable GAAP measures for the three and six months ended
June 30, 2023, and for the same periods in 2022:</FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended June 30, 2023</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GAAP</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization of Certain Intangible Assets</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gains</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Items</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Core</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Gross profit</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">23,470,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,649,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">26,119,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross margin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,352,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,843,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,195,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Loss) income before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,244,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,843,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">714,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(509,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,229,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,843,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">714,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(494,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted loss per share ($)<SUP>(1)</SUP>:</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.02</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted average number of shares of common stock outstanding, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,458,677</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,458,677</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Six Months Ended June 30, 2023</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GAAP</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amortization </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of Certain Intangible Assets</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Losses</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Items</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Core</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Gross profit</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">41,302,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,694,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">45,996,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross margin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,562,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,050,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,612,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Loss) income before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,175,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,050,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,328,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,614,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,839,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">303,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">303,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,872,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,050,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,328,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,614,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,536,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted loss per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.36</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.05</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted average number of shares of common stock outstanding, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,379,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,379,354</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended June 30, 2022</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GAAP</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amortization </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of Certain Intangible</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assets</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gains</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Core</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">Gross profit</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">16,789,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">341,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">17,130,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross margin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,690,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,088,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Loss) income before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,199,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,095,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">294,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,239,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,095,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">254,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic (loss) earnings per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.23</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted (loss) earnings per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.23</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighted average number of shares of common stock outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,303,458</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,303,458</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,303,458</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,234,177</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Six Months Ended June 30, 2022</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GAAP</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amortization </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of Certain Intangible</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assets</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gains</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Core</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">Gross profit</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">32,946,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">682,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">33,628,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross margin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,791,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">802,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,593,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Loss) Income before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,637,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">802,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,842,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,007,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,677,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">802,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,842,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">967,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic (loss) earnings per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.32</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.04</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted (loss) earnings per share ($)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.32</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighted average number of shares <BR>of common stock outstanding: <BR></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,265,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,265,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,265,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,270,639</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)
    </SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
    basic and diluted (loss) earnings per share is calculated using the weighted-average number of shares of common stock outstanding
    during the period. Core basic and diluted (loss) earnings per share also contemplates dilutive shares associated with equity-based
    awards as described in Note 2 and elsewhere in the Condensed Consolidated Financial Statements included in the Company&rsquo;s Quarterly
    Report on Form 10-Q for the quarter ended June 30, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment
Portfolio</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(includes
Non-GAAP Values)</B></FONT></P>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">At June 30, 2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Company</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares of Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Management</B></FONT></P> <P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Estimated</B></FONT></P> <P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Value</B></FONT></P> </DIV></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify">Eton Pharmaceuticals</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,982,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">6,917,180</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Surface Ophthalmics</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,750,000</TD><TD STYLE="text-align: left"><SUP>(1)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Melt Pharmaceuticals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,500,000</TD><TD STYLE="text-align: left"><SUP>(2)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Melt Pharmaceuticals &ndash; Secured Loan + PIK</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,066,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><SUP>(3)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Estimated Total Value</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">57,233,180</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>&nbsp;</SUP></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    a non-GAAP value, calculated as the purchase and conversion price ($4.50) of the Series A-1 Preferred Stock (the most recent equity
    offering) multiplied by the number of common shares owned by Harrow at June 30, 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>&nbsp;</SUP>Represents
    a non-GAAP value, calculated as the purchase and conversion price ($5.00) of the Series A Preferred Stock (the most recent equity
    offering) multiplied by the number of common shares owned by Harrow at June 30, 2023. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(3)
    </SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>&nbsp;</SUP>Represents
    the principal balance owed under the loan agreement, including interest paid in kind (or PIK). In accordance with ASC 323, Harrow&rsquo;s
    presentation of this loan receivable on its consolidated balance sheet is presented at its carry value less reductions in the carrying
    value related to Harrow&rsquo;s share of Melt equity losses. </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !< *\# 2(  A$! Q$!_\0
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MHHH **** #I3&9<8/?' !)Z],+R3GTSSCKD FXY( ).<#@]>>_3ISV/\Z_E
M_P""HW_!5C5?BQJ/B;]G#]F3Q1+IWPALWN] ^)'Q2\.WTL-[\6KA=]KJOA7P
M?JUI*DMK\*XV,]AJ^L6#I/\ $LK-;V=V/AX\C>.O;R'(<=Q#C5@\'%1C%1GB
ML544O886E)V4ZCC9RG+6-*C&2J59V4>6*G4A\KQ=Q?E7!V5RS',I.I4J-T\#
M@*4H1Q6.KI<SA24W:G2IQ:J8C$SBZ.'IKFFISG1I3_0G]M'_ (+1_"'X%7NL
M?#K]GS1[']H/XJV#RZ=>ZK8W\P^%/A;6%=K9M-N-:TEI-1^(7B"SN_)AN/#W
M@MH--\]I])OO&FDZY9W.FQ?IIX5\9^*?A7^S99_$G]IS7=+7Q=X)^%UY\1/C
M;JFA:5;Z9H6C:CI^AW'BSQ?I/A_3[:>=&TGPN@N?#F@F6^O=2U2STFQN-0O[
M[5+RXNYOY"O^"1_[."?M ?MD^!;K5=.6Y\ _ V*+XQ^+5:'%E/J'ARZA@^&N
MA,PC>!)+SQW)I.MFRFB:+4O#_A/Q%9!47>\/]('_  5 ^'7[1OQ_^#OA[]F;
M]G3PDNHWOQ=\3VMU\4?&VN:K;^'?!'@SX:>#+FQUN2SUO7IS)J#:CXI\8OX6
MA@T/PYI?B+6M3\,Z3XN632#IXN)E^GXAR3(\LS/)N',/4A1E>&*SO.,74@JJ
MI37,HJ7,J-"G#"T,37IX?#TW[2M7PMYUY6/@.#N*>*<ZR3B7C7'4*N(BH5,!
MPQP]EN'G.A+$4&HSG&'+]8QE:IF%?"86IC,35CR4,-CYOZI3E.$/XY/BY\:?
M'7QJ^+'C_P",WBC4]4M?$OQ"\8:UXNN+:'5;XIH46J7CS:5X>TN=)DECTWPM
MI(L/#VEA2"NGZ7;D[GWLWH?PO_;1_:V^#-Y;7?PU_:,^+6AQVCAX=&U+Q;?^
M,O"9&T(R2^"O'3>)O"$H= (R\FAF55PT<L;HC)^M6D?\&^?QGGT<7.N?M)_"
MW2==$6\Z1I/@+Q?XCT@2XSY?_"1WFN>%[LQGIYX\*1NN2?L[<J?SV_:M_P""
M:W[5'[(6F7/BWQYX7TGQG\,+4PB[^*?PSOKWQ#X7T,W,XM[=/%]CJ&G:-XG\
M)+)*\,!U75=$_P"$5^V75IIT'B6YU"ZM[>7]3PN><'YDZ.5T<9E.)2IPPV'P
MN(HP4)QIPA0ITZ/US"TH3_=PA&$8U(3FM5K.:?X/C^%O$7(E7S_%X#/<#)U*
MF*QF8X7%S]K3J5:D\35KXMY=F%6K0C[6=2I.I5IRH4E93=.G24H?KA^R1_P7
M=T[5KW3?!7[8GA*Q\+R3F&TM_C1\.K#49?#:2%HT27QWX!>;4]9T2%PC27GB
M+PC?:]9F[N%+^$/#^DP3WL?]$GAWQ)X>\5Z%H_B;PMKNC>)?#GB'3K76- \0
M^'=2L]9T+7-(OXEN;#5='U;3I[JPU'3KZW=+BTO+*XGM[B%UEBD96S7^;B<D
M].1CMW!!]>@/89QD$9XQ^E'_  3S_P""C7C_ /8I\76_AW79-7\:_LY^)-3W
M^-/A\DK7=_X3N+Z;-[XX^&<<\JPZ?KD#NU[K7AE'@T?QK"L\5T+#7I+#Q#9?
M*<3^'>'K4:N/X?@Z&(IQE4GEEV\/B(I\TOJ?.[X:OR\SA0E)X:JUR1>'DX(_
M0.!?&7&X7$4<KXPJO%8*I)4J>=R@HXO SE)0B\R5.*6+PD6X1JXE4X8S#IRJ
M588F$*DH_P!P=%<EX%\=>$OB7X/\->/O >O:=XH\&>,-'LM?\,^(=(G-QI^K
MZ/J,,<]I>6[E(Y(PR2;)K>XCAN[2XCFM+N""Z@FA3K:_%I*492A*,HSA*4)P
MDG&4)P;C.$HR2E&49)QE&24HM--)G]/0G"K"%2G.-2G4A"I3J0E&<*E.I&,Z
M=2$XN49PG"49PG&3C*,HRBW&2;****184444 %%%% !1110 4444 %%%% 'R
M=^V]\)OBI\</V6_C'\+?@QXP;P7\0_%WAB2QT>^\R*TAUVTCNK>YUOP-=ZK)
MB70[+Q]HD6H^#[K7K9TDTB+63>N9+6*XAF_@6UG0]9\,:QJWAGQ'HVI^&_$7
MAO4[[0O$'AW6K&?3-9T#6M)N9++4M%U;3+A4N+'4=.O();6ZLYHUDAD0KC&U
MF_TF"JG)V@D^HZD=,U^3G[>G_!*SX8?ME>*_"WQ-T74XOAC\3XM<\):5\2-<
ML;)GL?B;\,;;4K#3]?M=8M[/;+!\1?#_ (32[A\!>,0)6F2TL/"7BF&ZT./P
M_JO@O]"X%XMPV0SQ& S&*C@,7-8A8JG2YJU'$4Z;BH5>2TZN'JQCR1^.>&J2
MC.$?95*\H_C'BOX>8WBN&$S;)YNKFN I?5)8"O7<<-B<'4K>T<\/SM4L/BZ-
M2K*K5=X+&8:-2G.4L11PW-SO_!%3]G#_ (4S^R3:?$S6[ VGC3]I#4+;XBW4
MDT,D5W#\.K&"?3OA7IK.Q FLKW1KG4_'U@X165/B!)"2ZQ(:_6.3Q/X<C\46
MO@M]9L?^$LOM O\ Q5;^'Q*KZG)X<TO4=,TB]UEX ',-E'J>K6%E'-.8A=SR
M7"V@G^QWIMX99/#/P]\(2R_9[/P[X/\ !'AB1_L]I;B*QT3PQX8TK=]GM;>!
M,1VFEZ38B*W@B3"Q0)&BCC'\YTW[2WQ*;X\7O[0VF7R6?BRZU*XDM-+U!3?:
M1;^$I$-I9^!;ZTCDMQ<:)#I*P6ER+6:SN)=01_$%M<VVMLM^OQ^8XVOG&88_
M,JS2GB\35K\KVC"4K4*4>B5*C"C373W'96:1]E0G@>",DR#)H0]M##T:.&J3
MB^64HTDGC\<TDKU:V*JUJD8IP<IU+WM$_I84';@$G (Q@$D^YR.2?IP>W6O%
MOAW\5O ?QQM_B/X9MH;6\N?!/BKQ3\.?'WA/5DM-0AD2QU'5="^TRVLBR6VK
M>%/%MI87DEC+/;FVNX5U#2KV%+RPU"U7\Q/%W_!37QYK'A:?2O"?PVT7P=XF
MN[-K23Q5<>*+KQ+%IKRQM%)?:1H$OA_28EOE9C/8R:KJ6IVMI,(_M=GJL:21
M2_)_[,?QFO/@I\9O#GC.]OYV\/ZM=?\ "/\ C]IYY9OMGAG7;F!=1U6]DE\V
M2XN]$OQ:^)EGP;N=].N;42A-1NS)QJC)1<F^62LX6;O=-.]HO=-*S6J=FFK)
MJZ_%N 6-P-'#25?#5Y2IXVI*E*FH1KJ%.DX*JE)NG4DY5DX.FZ;G!W47*7Y[
M?\%5/V$[7]CGXR:?XC^'6GSP? +XO2:E?^![4>=<1> /%.GB&X\3?#::[=I6
M.FQQW*:]X%DNY4NI_#\VHZ(J7K^#+_5[W\L7=(HWDD9(XXT9I)'(5(T4%G=V
M)"JJKDL2<+R<A037][?_  4"_9L@_:J_92^*7PNM;&&]\:6VDR>-_A?,4C:X
MM?B7X-@N=4\-0VL[D"S7Q,!>^"-3NE#/%H7BG5A''(7"-^/_ /P3._X)":AI
M5]X9_:'_ &O?#2VNH6?V+Q%\-_@'K=O%--IMV%CN]+\5?%VS+/;KJMFS1WFC
M_#:4.^CW207?C4)K4+^%]$_:^'^/,)2X:GB,XQ+J9AET_JBI)J6+S%^S4\)4
MA&4O:5)2IJ5/%XB25.$J*JU9RG74*GX-Q?X49E6XVAA.&\'[#*,XIK,/K*A*
M&79*E5E2S"C*I"*4*<:DH5\!A*7-6JTL1["C3C2H*='[6_X(R? GXX_!/]ER
M6;XOZMJFGZ1\2/$?_"=?#7X2ZQ9F'4/AEX:U&U9KS4;\W44>H:/J/Q'O)HO%
M-WX+.+7P_&MKJUU!8^+?$_B^PL_U]I,#). "223@9R>I..__ .H<4M?CF9X^
MKFN8XS,:T*=.IC*\JTJ=&*C3IW2C&$4DF^6$8*525ZE6?/5J-SJ/E_I3(<GH
M</Y/EV38:K7KT,NPM/#0K8F;J5JKCS2G4FVVHJ52<W"E#]U0I>RH4DJ=**"B
MBBN$]<**** "BBB@ HHHH **** "BBB@ HHHH Y+QWX,T7XA^$/$?@;Q$MZV
M@^*=)N]%U9=.OKC3;U[*\54F2"\MF62)F4;7!WQ31E[>XAGMY9HF_+/QO_P2
M]NEFGN/AK\5(GMF9OLVD>/=%87$:XRHF\2^&PL,_S\97PE;E5 )\Q@0WZ\T5
M49RA?E;5SS<?E&7YERO&8=5)TXN-.K&=2G5A&3NXQG3G%\K>MG&2OJ?A9_P[
M0_:#,NP^(O@X(LC]^/$_C(\=_P!S_P *Z$@/H"V/^FG2O8? _P#P2])DBF^)
M_P 4S-:YQ<Z'X#T989)$*\HOB7Q']H4(3E' \*[RF626%RIC_7*BK=:H^MO1
M?CUU]+'FTN$\DIRYGAZE;^[7Q-:I3])03IJ2[J3=UH[ZF/X?T6U\.:'HOA^Q
M>[EL= TC3=%L9=0NI;Z_DM-*LH+"VDO;V?,]Y=R06Z-<W<Q,MQ,7ED)=VK8H
MHK(^C244HI622271)))+Y))?)!1110,**** "BBB@ HHHH _GB_X).?\%\])
M_P""I/[2_B[]G.P_98U?X(3^%/@7XM^-C>+K[XQV/Q"M[^+PKX_^%O@5O#:Z
M);?#?PA);S7S_$U-3753JDR6R:*]H=/F:_6XM/N;_@J__P %'[+_ ()=_LV>
M&OVB+[X/WWQLA\1?&+PM\)%\(V'CFW^'\UI)XG\+^./$RZ\VMW/A7Q?'/'9+
MX*>R.FC2XGN&U-9UO8?LIBG_ (2/^#=7]I5_V5?V[/B3\28_V?/VFOVE3JW[
M)/Q&\#_\*_\ V3_A?;_%SXEZ6-5^,?[/NNMXPU;PQ<^)/"\=GX(TW_A&5T?5
MM=&HRM:Z]XA\,Z>+*8:FTUM^M'_!Q)_P4"E_:H_88\#?#I_V'/\ @H;^S8NF
M?M-?#[Q>?'O[5W[.5C\)?AOJ!TSX?_%K2QX7TWQ-:^/O$\ESXNU#^V_[1TS1
MSIR+=Z9I&M7!NX6LE63]"QW#6%I\5X/ T,%)914>!5:+Q<6VZE'$RK7E4QD,
M6KU(4[J%)KW9>RER2YHA_4]_P3;_ &UK7_@H;^QU\+_VMK/X;W7PEM_B5J?Q
M)TU/ 5[XKA\;7&C'X=_$[QA\-I)G\26^@>&(KX:M)X2?6(T71;4V4=^MDSW+
M6YNION<]/R_'GI^/0U^$G_!M1_RAK_9;_P"QH_:7_7]J/XQG^M?N%XD\1:#X
M0\/:]XL\5:QIWAWPQX7T75?$7B/Q!K%U#8:3H6@:'83ZGK&LZI?7#QV]GIVF
M:=;7%[>W4TB16]M!++(ZHC,/C,UH4L-F>887#P<:-''8FA0IMRG)0A6=.G"\
MFYRE;EC=OGE)K7F8=3\0/^"P7_!;SP+_ ,$IO&/[/GP__P"%6#XY>-OBM<7O
MC/X@>%['QH/"VK?#?X%Z-J=OHEWXUM;1/#NOR:YXG\5:P=;T[X>^'[LZ-I6N
MW/@KQA%>Z]IC6,1F_;?PAXM\,^/O"GACQSX+UO3_ !-X.\:>'=$\6^$_$FDW
M"7>E>(?#/B33+;6=!US3+J,E+G3]6TJ]M;^RG7"S6T\<BC:PK_.(^*?[.OQR
M_P""W?AK_@K%_P %=]-/B6V\+? W4M&T3]EKX>RVL:/XK^&7PC6R\3>,_!KZ
M==M-J6FZKX&_9QFL?'LFBZ$DL/BSXZ?$K7],L9/M5MJ5D_\ 0=_P:Q_MSK\?
M?V,=?_9,\8:T+[XD?L=:G8:9X7:]NVEOM>_9Y^(-SJ^J_#BXMI+B??>1?#[7
MK/Q;\-?L>FVPLO#7@S1_AE;W;K/K=LUQ]%FO#V&PF2TL1AJGM<PRRO3P^?1C
M)R5.KC:4,12CRZJ*PCJ4\-.4%&,I3ES-SIRL']1?2OYD/VA?^#B?Q-\(_P!O
M_P ?_P#!/3X7_L">)/CU\5?#7Q4T3X2>"KW3?VD/"7P_;XC^)M>\*>'O$]A%
M:6/BGX;OH?AHRC739#^V_%WV)&LVN)]1A$RQ1_TW]?\ /^?\^]?YJ7[4OQ1\
M._!'_@YN\>?&'Q?8^*M3\*_#3]M?X<^,?$-AX'\+:SXW\876DZ/\)/ ,]Y'X
M=\(^'K:]USQ#J(C/F+INEVD]W)"DTJ1E87QS\+9;A,RK9DL5A_K7U;+*V)P]
M+VE:FI8B$[4TW1J4I2YFE#E<DO?;TERN(?TAZU_P<B:+^SE\?-+^ ?\ P4@_
M8%_:(_89U?5[32-6B\4S>*_!WQU\-:;X9UF]ELXO'.H3>"['0;CQ%X&LI[/4
M[74]8^$Z?%#5+#4M-OM)?07U*RU&VL_Z5M#US1O$VC:3XC\.:OIGB#P]K^F:
M?K>@Z_HE_::KHNN:+JUI#?Z5K&CZI837%CJ6EZG87$%[I^H6<\]K>6D\5Q;R
MR12*Q_SS?^"DO[0OBW_@X^_;'_9]^"?_  3E^"NN:IHWP#^'GQ#N[GX@?%;4
M?"OP\:\T7XD>*_AM9^+_ (D>++8ZWK%YHOPA\ MX<\'1Z7]B77_B#K6I^*]9
MM=-^'SZA<:+8:U_>?^RW\$X_V:OV9_V>?V=(?$5SXOB^ GP/^%/P9C\67=JU
MA<>)D^&/@70O!@U^73C=7PTXZO\ V,;]=.6]NTL$G6SCN)D@5S.?Y=@L%A<J
MJQH/+LTQ-.I+'Y2J\\0L/3][V%=^UE4JX>55QM[&=:JY)N:LHW8?E5_P6!_X
M+4Z5_P $F/$_P \.:G^SEJ7QW_X7OX=^*OB&*^L/BG:?#E?"J?##4?A]I\UK
M+;W/@'QFVL'6!X]CF66.;3_L/]E2(T5W]L5K?Y2^)?\ P<)?M!?LZ_#SX4?'
MC]J'_@D'\??A5^SA\8(/#&H>#_B_X1_:%^#_ ,6+/4]-\8:%#XG\--'INC:/
MHNFZ'J_B'P]/_:&@:'\0?$W@*]U9XKFPB:.\L[V&U_,?_@\<4O\ $W_@GTH(
M!;X;?M9*"3@#/B/]G89)XP!G.20!ZCK7!_MW_P#!7[X0_M+_ /!,KX _\$F?
MV=OA!\9?&O[2/Q'\ _L3?"#Q1_PG'@@_#C2O#7B'P6?A!XKT'2O!]IXMU"R\
M0^*_%'Q#\2^'/">E>"KO^Q=(\&ZGX0\7?\)E9>+[I#HVFZW[F6Y#@<1E7#^)
M_LEXR68U\5#-<0\7BZ/U3"4IUU+%PE3K0HTO84XJ34Z52,^1*T93N@_M%_8S
M_;+^ G[>?P$\+?M&?LY^*9_$G@+Q%<7^D:A8:O9?V-XP\#^,-%>*/Q#X$\>^
M''GN9O#_ (KT-[BVFFMA<7FF:OH]_HWBKPQJNO\ A#Q#X?U_5/HGQ1XH\->"
M/#?B'QGXT\0Z'X0\'>$M$U;Q-XL\6^*-8T[P_P"&O"_AK0K&YU37/$7B+7M6
MN;/2]$T+1=+M+G4=6U?4KNWL=.L+::ZNYX;>&21/Q6_X(!?\$Z_C#_P3E_8M
M\0>"/V@;BQL?C%\:?BWJOQI\7^ ='UG3_$.E?"V.]\&^"_ VB>"9M?T:YO=!
M\0>)X=)\%6^L>+=8\.WE[X?CU753X=T75/$.F^';;Q-K?Q%_P=H_''QEX _8
M3^#OP:\+WM]IFA_M"?M!Z?I/Q(N+61XX=9\%_#7PCKGCVU\(WC( 3;:GXZM/
M!/B"6+S4^U0^$IK.6.>RN;N)OEUE6&QO$']DY;B?:82MCIT*&+DU*V'495*E
M6\5&%5TH4ZT8R48PJNG&HHJ,V@/=O!W_  7E\9?MC_&7QE\'/^"4G[!OQ%_;
M0L/AS;6USX]^._Q.^)^B?LK? _0;34[RZM-"U>RU+Q/X4\:>*K^Q\2&QOV\.
M:%XBT'P1\0?$"Z3XAU'1O!-]X?\ #^IZU$?$#_@NY\1?V*_BWX%^&'_!5;]@
M+QY^R)X:^)@N/^$'^/OP=^+6@_M5_!S5H]/O(+?7+[4SX=\(>!_%NG0^&XKF
M*YU[P[HFC^+OB39VESIVJ1^ )]%U.TU1M7_@U_\ A9X8\#?\$E?A=XZT:TMX
MO$'QT^+/Q]^(?C>]CC03WVL>%?BOXE^"6C)/*!YC1V7@_P"%'AZ&"%F,<4C7
M$L:J;F4OU?\ P<O_  V\+^//^"0?Q^\0:Y86UQKGP@\;? 7XF^ M1GY?0_$T
MGQJ\#_#?5KVU!QFXU3X>?$3QQX7SD$1>()"OSA*]-T<G7$']AK+?]C6.CE;Q
M?UG%/,G6E4CAOK7M/:1PR:Q+O[#ZI['V2:U=I!_7]?\ #G[B>!O''@WXF>#?
M"_Q#^'?BG0/&_@/QOH.E^*/!WC'PKJUCKOAKQ3X;UJSBU#2->T+6--FN+#4]
M+U.RGANK.]M)Y89X)$=7YP/Q]_X*]_\ !7C7O^"3\'P0UZ^_96U/X^^!/C5<
M>.-#3Q?I7Q;C^'<'@[QOX0M]%U2R\):U:7?PS\86\\OBWP]JFI:UX<NX=42:
M>/PCXMBN--A33(+B_P#S-_X-&?CQXV\:_LI?M*_L_>(K^]U7PG\ /C#X;\0_
M#:2]N)IT\-Z#\;=$US6O$'@K2(I&,-KHUIXX\&^)/'*6T:A_[9^(>O3NYCGA
MCB_7W_@MI^QG/^W%_P $X?C]\+?#NCMK/Q3\#:3%\=?@E!;V\ESJ<WQ0^$T5
MWKUGX>T2%"$.J_$;PDWB_P"%$,LJR1V\7CR>XQ')%'-%P++\)EG$D,MS-?6L
M#3QD*%67/.ASX?%0INCB'*E*,Z<J2Q-"I42;2M433A=)GV_^RC^T9X*_:Y_9
ML^"'[3/P[WQ>$OC;\./#7CVPTR>Z@O=0\-WNL6$3:]X-UFYM0MLWB'P3XACU
M;PEXC2%%2#7-$U&%57RB*X#X ?ML_!W]HWX__MC?LY> ;V6Y\>?L5^/_ (>>
M!/B0XN;.ZTS5G^(GP]T_Q?8:QH<UK([+;Z/XF@\=?#/7K*ZQ>Z=XP^'GB""=
M5B>TW?R0_P#!NS_P5:\&_L\?\$\OVY?AY\6];@U"U_8Q\)^)/VK_ (-Z!?:F
M;2X\5_#_ .($1M-3^&7AA?L\T<4DG[04FB1Q7#EO-\2_M$:-9QPB*)2/S"_X
M(<_MG_%']F?_ (*V?#;QO\?;_7;>#]OVXG\'_%W6?$5E=6B^,=;_ &IO$-MX
M]^$WQ9LK6;R;>XM?$GQLN?#L&F>(%=["P\)>.?%SV\@C:X0^J^#ZW/Q-%2G_
M ,)<7/+;N-\7=?7K1NU[11RQ2NDI?O5'F:E)L1_;/_P5(_X*MZ9_P3CU;]F'
MX=^&/@5K'[37QW_:Q^)%UX ^&'P@T#Q]8_#V\F6VN?#_ (?BU:YUVY\*^,RL
MFI^//'/@/PAHVFR:+!'?OK.KZFFJ1IX:NK.Y]F^*?[9GQ)^'?[3]A\"-.^!>
MK^+-&F\'7&OKJNC)XAO-6\1ZK'I>CZC'IOA>6VT1K%HY!?\ B-[1[FQN;6^L
MOAC\1I)M4TG5M-L-#O/P-_9[0_\ !4[_ (.1_CE^T+=(VO?LY_\ !*_PPWPH
M^'KO;PW&A7_Q7\/ZKXS\!Z"\T1<6MY->_%O4?VA?B7X=\3V7VF6>S^%7PSG\
MUK2/294_L"[@]P" >X!() /4 D D#@D GH*\?,,-@\MC@,-+#JKC99<L5F$I
M5JL5"OCW[;"48P3<(?5<'[&4[14YU,3+VEN2* _SH?\ @TBO+.Y_X*<?&!+>
M[MIW'[!WQ=8K!/'(P4?M!?LJC<0C,0H)49Q@%A_>&?W;_P"#M2:&W_X)G?#-
M[B:.%#^V9\*E#S2(BEC\*_CJ0NZ0HN>"0N<G!ZU_1IX-^"?P:^'.K3:_\/?A
M)\,? >N7.GS:3<ZSX+\ ^%/"NJW&E7%S:7ESID^HZ%I-C>S:=<7>GV%U/8RS
MO:RW-C9W#PF:U@=.B\9^ ? OQ&TJ+0OB%X+\)^.]#@OH=3@T;QEX;T;Q1I,.
MIV\-Q;V^HQ:;KME?V<=_;P7=W!!>) +B*&ZN8HY%CGE5^W%\14L3Q+A<_6#J
M4X8?ZK?#>VIRJ36'HXBE)JK[/DC*:KJ2O'E3@[I\S _$W_@VEEBF_P""-'[+
M4D,D<L;>)_VE]KQ.LB''[4?QC!PRDJ<'@X/!KY^_X.7/VPO$_@/]F[X9?\$^
M?@0\NM_M-?\ !13QKIWPFT7PGHM[&GB"7X3'Q%X>T;Q1IL8BNU>PD^+GB_7_
M  A\'[>/5[)M,USP=X@^*DUM<PS^%[JXM?Z/O"OA#PIX$T.T\,>"/#'A[P=X
M:T][N2P\/>%=$TSP[H5B]]=SW]Z]GI&CVMEI]L]Y?75S>W3PVZ-<W=Q-<S%Y
MI7=LC5OAC\-]>\6:-X]UWP!X)UKQUX<AAMO#WC35_"?A_4O%N@VUO/>W-M;Z
M+XDO=.GUK2H+:YU'4+BWBL;V!(9[^\E0+)=3M)Y\<THO/:F<5L(ZT'C<1CH8
M.52"C[:<IU,-&K/D<9TZ-=TJE6,8IU52Y(\O-=!^!_P&_P"#>C0/@G\(? _P
MU\-_\%0O^"LGPUAT70[:3Q'X1^ '[5OASX5?!I?&^K(=4\>ZEX(^'UK\&[T:
M%H'B#Q;>:SJ]K9:IJ&LZP;>^0:UK.KWYN+^?^87P_:WW_!NE_P %S?#OA[5?
M$NOO^S5=R:'H-UXK\63Z=#J/CW]C#X\R6&GW/BG7SHNFZ/INI:I\%OB!X=?5
MM?DT/0=(CUOQ1\#[X:/HVEZ7XEM]-;_2C_'_ #_GZ>_/->:^-O@S\(/B7=VF
MH?$?X5?#;X@W]A9R:?87WC?P+X6\67EC82RM/+8V=UK^E:A/;64DSO,]K"Z0
MO*[R,C.Q:NS+^)L73GCX9K[3,\'F6%Q&'Q=!_5J,Y3K)N->%2.$A>I3FU9U9
M5I*'+&,HR@I >B6\\-Q;PW-M-%<V\\23V]Q;R)-!<02J)(9X)HR8Y8IHF22*
M2-F1T92K,I!/^<O\1;VU7_@[(@@-S;B=O^"@?PE183/&)B3\*? :D"/>')()
M& .A(((X/^C)8V-GIEE::;IUI;6&GZ?;065A8V4$5K9V5E:Q)!:V=I:P)'!;
M6MM!''!;V\$<<,$*)%$BHBJ/.9?@C\&9_&'_  L.?X2?#&;X@_VE!K/_  GD
MO@#PD_C/^V+:&.WM]6'BAM'.MC4X+>&&"'4!??:XHHHHXYE1% Y,ES:.4_VC
MS4)UUCLNKX"/+4A!TY5N;EJ3YHRYXQYKRC#EDVM&DV!_"3_P6D_89^*O_!'K
M]M;X=?\ !4[]A6.V\%_"+Q-\3I/$=QIFFV4Y\(?!+XU>(5O/^$L^'GB;1+*6
MQ2#]G_\ :'TN]U^RT_2;.]MM-T34M4\7?#S2[SP=#<_"2TF_LH_X)Y?MX_!W
M_@HY^R[X&_::^#EQ':6FN&?P[\0? <^KV6L:_P#"7XIZ);64GB_X:^)[BR2!
M9;_2'O[+4]%U1[+3E\5>#-9\+^,["P@TKQ%8J/K[Q-X3\+^-="O?"_C'PYH/
MBWPSJ8MQJ7AWQ/H^G:_H6HBSNX-0M!?Z1JUM>:?>"UO[6VO;<7%O)Y%W;6]U
M'MG@BD3$\$_"_P"&?PRBU&#X<?#SP+\/8-8GM[G5X/ _A'P]X2AU:XM(I(;2
M;4X]!T_3TOY;6&66.WENQ*T$<DBQLB,P+Q^<1S++<%A\7AYSS+ ?N*691J4T
MZV!2BH4,33=-3J3I))4ZJGHH1O=2G</X@/\ @\ENK>V^)7_!/HSW$%OGX;?M
M9;3-+'$"W_"1_L[D!?,903A2<9YP?2O<?^"IW_!(8_M=_P#!,#]C7]M3]G;P
ME_:7[3/P0_8C_9W7XC>&/#\,KZM\>_@;HOP9\,:E/:V&GV@:36/BE\+$DOM?
M\#MI^W7?%GA:?Q'X"AB\0ZVOPUL=%_L%\;_"+X4_$Z739_B1\,OAY\0IM'BO
M8-(F\=>"?#7BV72K?4FMI-0M]-DU_3+][&"_>SLWO8K9HDNGM+9IP[01E>VT
M_3-/TC3['2=)LK32]+TNSM=/TS3=-MH+&PT[3[&!+6RL;"SM8XK:SL[2UBBM
M[:UMXHX+>"-(H8XXT51VT.)\1@\'D6'P=&5*MDU;%5)U)5(RI8REB7+FP\J:
MCS1A*,Y1GS.:NH3BE4A%@?SA?\&[_P#P6%L?V_/@C_PSE\;?&<.L?M@? 'PQ
M92:CKNH:K:W6H_'[X/VTUMI.A?%R!FG:[O\ QEX=>YTKPI\8P@NUGU^Z\.^/
M/M-O'\1/[ \._:7_  6U_P""=FK_ /!2?]B'7_A+X GTRS^.7PV\7Z/\:/@1
M-K-Y#INC:KX\\-:5KN@:AX*US59(96T[2_'O@KQ/XI\,6]\\D.G:/XGN_#7B
M36!<:;H5S:S?I!X;^ GP,\&^(;;Q;X/^#'PG\)^*K,WK6GB;PS\./!N@^(;5
MM2AFMM1:WUK2]%M=2@-_;7-Q;7ODW*?:[>XGAN/-CFD5O6,<Y_S]?3KSR#SR
M,')/EU\QA3S=9IE.'EEZA7ABJ-"52%6%&LN:52--QA33P\Y2G:C*-XTYSI7:
MY6!_&;_P;S?\%'/AG^QY\/O'W_!,#_@H!K]O^Q]\:OA#\2?%?C'X7:?^T=<V
M_P )-(U3PG\1+M/$7B'P1+K?C&33=$T_Q3IGQ G\2>)] EOM6@TOXC^&O'.D
MW7PZN_$D6CZQ-'T'_!P[_P %-?@W^TK\#_#G_!,S]ACQ?I?[77QU_:&^(/@C
M4?B'H7[.,L7QD@\/^"?AGXGTOXAZ/X6M=6\!2ZU9:GX_\3_$/PUX2GF\/:%/
MJLOACP9X=\6:EX_;PO::GX7;Q!_5C\7/V>/@!^T!IUAI'QY^!OP>^-VE:6TC
MZ9IGQ>^&7@GXE:?ISS!!*]C9>,]#UFWLVE"+YK6T<1? W$X7$'PA_9M_9W_9
M\MM0L_@'\!/@K\#K/5A&-5M/@]\*_ OPSMM3$3[XEU"'P9H6C1WBQO\ ,BW
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MR:9HVLIXEOO%.G:1HNJ6UOJ-UHNFP7NI:G,VOK;:;96.J?H?\!O@I\./ WP
M^&WPPLO#&BZQX;LOAK\./#^KG7]!\.7=WXU_X17PCX?T73M;\<1VFC6&E^(M
M?EMM'L)[K4)],C0W<"26MO:QQPQ1]9X]^&G@J^^'_CS2+3P_H^@'4_ASX_\
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GRS!9G63Y_K;HNA5FYRG*:G"-J48+]VZ5.G%^R4ZM)U*M.&'<?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-2_001.jpg
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !< *\# 2(  A$! Q$!_\0
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MHHH **** #I3&9<8/?' !)Z],+R3GTSSCKD FXY( ).<#@]>>_3ISV/\Z_E
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M\MM0L_@'\!/@K\#K/5A&-5M/@]\*_ OPSMM3$3[XEU"'P9H6C1WBQO\ ,BW
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MR:9HVLIXEOO%.G:1HNJ6UOJ-UHNFP7NI:G,VOK;:;96.J?H?\!O@I\./ WP
M^&WPPLO#&BZQX;LOAK\./#^KG7]!\.7=WXU_X17PCX?T73M;\<1VFC6&E^(M
M?EMM'L)[K4)],C0W<"26MO:QQPQ1]9X]^&G@J^^'_CS2+3P_H^@'4_ASX_\
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GRS!9G63Y_K;HNA5FYRG*:G"-J48+]VZ5.G%^R4ZM)U*M.&'<?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>hrow-20230809.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCICbP9z5Z8yekhvWB8bemaHyMv+yjPMykJUIY28QAF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:hrow="http://harrow.com/20230809" elementFormDefault="qualified" targetNamespace="http://harrow.com/20230809">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://harrow.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="hrow-20230809_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="hrow-20230809_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="hrow-20230809_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="hrow_CommonStock0.001ParValuePerShareMember" name="CommonStock0.001ParValuePerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="hrow_Sec8.625SeniorNotesDue2026Member" name="Sec8.625SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="hrow_Sec11.875SeniorNotesDue2027Member" name="Sec11.875SeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>hrow-20230809_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrow.com/role/Cover" xlink:href="hrow-20230809.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrow.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20230809.xsd#hrow_CommonStock0.001ParValuePerShareMember" xlink:label="loc_hrowCommonStock0.001ParValuePerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_hrowCommonStock0.001ParValuePerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="hrow-20230809.xsd#hrow_Sec8.625SeniorNotesDue2026Member" xlink:label="loc_hrowSec8.625SeniorNotesDue2026Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_hrowSec8.625SeniorNotesDue2026Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20230809.xsd#hrow_Sec11.875SeniorNotesDue2027Member" xlink:label="loc_hrowSec11.875SeniorNotesDue2027Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_hrowSec11.875SeniorNotesDue2027Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_deiEntityInformationFormerLegalOrRegisteredName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInformationFormerLegalOrRegisteredName_50" xlink:type="arc" order="58" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>hrow-20230809_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20230809.xsd#hrow_CommonStock0.001ParValuePerShareMember" xlink:label="hrow_CommonStock0.001ParValuePerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrow_CommonStock0.001ParValuePerShareMember" xlink:to="hrow_CommonStock0.001ParValuePerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hrow_CommonStock0.001ParValuePerShareMember_lbl" xml:lang="en-US">Common Stock, $0.001 par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20230809.xsd#hrow_Sec8.625SeniorNotesDue2026Member" xlink:label="hrow_Sec8.625SeniorNotesDue2026Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrow_Sec8.625SeniorNotesDue2026Member" xlink:to="hrow_Sec8.625SeniorNotesDue2026Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hrow_Sec8.625SeniorNotesDue2026Member_lbl" xml:lang="en-US">8.625% Senior Notes due 2026</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20230809.xsd#hrow_Sec11.875SeniorNotesDue2027Member" xlink:label="hrow_Sec11.875SeniorNotesDue2027Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrow_Sec11.875SeniorNotesDue2027Member" xlink:to="hrow_Sec11.875SeniorNotesDue2027Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hrow_Sec11.875SeniorNotesDue2027Member_lbl" xml:lang="en-US">11.875% Senior Notes due 2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xml:lang="en-US">Entity Information, Former Legal or Registered Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>hrow-20230809_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrow.com/role/Cover" xlink:href="hrow-20230809.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://harrow.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20230809.xsd#hrow_CommonStock0.001ParValuePerShareMember" xlink:label="loc_hrowCommonStock0.001ParValuePerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_hrowCommonStock0.001ParValuePerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20230809.xsd#hrow_Sec8.625SeniorNotesDue2026Member" xlink:label="loc_hrowSec8.625SeniorNotesDue2026Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_hrowSec8.625SeniorNotesDue2026Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20230809.xsd#hrow_Sec11.875SeniorNotesDue2027Member" xlink:label="loc_hrowSec11.875SeniorNotesDue2027Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_hrowSec11.875SeniorNotesDue2027Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_deiEntityInformationFormerLegalOrRegisteredName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInformationFormerLegalOrRegisteredName" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140106272044848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  09,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HARROW
HEALTH, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001360214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0567010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">102
    Woodmont Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-4730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not
Applicable<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrow_CommonStock0.001ParValuePerShareMember', window );">Common Stock, $0.001 par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock,
    $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HROW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrow_Sec8.625SeniorNotesDue2026Member', window );">8.625% Senior Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">8.625% Senior
    Notes due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HROWL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrow_Sec11.875SeniorNotesDue2027Member', window );">11.875% Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">11.875% Senior
    Notes due 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HROWM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrow_CommonStock0.001ParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrow_CommonStock0.001ParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrow_Sec8.625SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrow_Sec8.625SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrow_Sec11.875SeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrow_Sec11.875SeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:hrow="http://harrow.com/20230809"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hrow-20230809.xsd" xlink:type="simple"/>
    <context id="AsOf2023-08-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="From2023-08-092023-08-09_custom_CommonStock0.001ParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrow:CommonStock0.001ParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="From2023-08-092023-08-09_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrow:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="From2023-08-092023-08-09_custom_Sec11.875SeniorNotesDue2027Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrow:Sec11.875SeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-08-09">0001360214</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AsOf2023-08-09">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="AsOf2023-08-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-08-09">2023-08-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-08-09">HARROW HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-08-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-08-09">001-35814</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-08-09">45-0567010</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-08-09">102     Woodmont Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2023-08-09">Suite 610</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-08-09">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-08-09">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-08-09">37205</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-08-09">(615)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-08-09">733-4730</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName contextRef="AsOf2023-08-09">Not Applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:Security12bTitle contextRef="From2023-08-092023-08-09_custom_CommonStock0.001ParValuePerShareMember">Common Stock,     $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-08-092023-08-09_custom_CommonStock0.001ParValuePerShareMember">HROW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-08-092023-08-09_custom_CommonStock0.001ParValuePerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2023-08-092023-08-09_custom_Sec8.625SeniorNotesDue2026Member">8.625% Senior     Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-08-092023-08-09_custom_Sec8.625SeniorNotesDue2026Member">HROWL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-08-092023-08-09_custom_Sec8.625SeniorNotesDue2026Member">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2023-08-092023-08-09_custom_Sec11.875SeniorNotesDue2027Member">11.875% Senior     Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-08-092023-08-09_custom_Sec11.875SeniorNotesDue2027Member">HROWM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-08-092023-08-09_custom_Sec11.875SeniorNotesDue2027Member">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="AsOf2023-08-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-08-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-08-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-08-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-08-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MP_SE;H#OEPI"LC]Q.Z7%1O?@?U!+ P04    " "S@ E7X/0ZB:H"   P#
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M1AS!&  '#$G3_CUX]SY*QO=4<OF/L/D)4$L#!!0    ( +. "5>7BKL<P
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MCEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0    ( +. "5<D'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ LX )5U*8LK?O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MLX )5YE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "S@ E7U?NZ3RL%  #T%@  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MLX )5^#T.HFJ @  , P   T              ( !;PT  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " "S@ E7EXJ[',     3 @  "P              @ %$
M$   7W)E;',O+G)E;'-02P$"% ,4    " "S@ E7JL0B%C,!   B @  #P
M            @ $M$0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ LX )
M5R0>FZ*M    ^ $  !H              ( !C1(  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ LX )5V60>9(9 0  SP,  !,
M         ( !<A,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  O!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrow.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex99-1.htm</File>
    <File>ex99-2.htm</File>
    <File>hrow-20230809.xsd</File>
    <File>hrow-20230809_def.xml</File>
    <File>hrow-20230809_lab.xml</File>
    <File>hrow-20230809_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "contextCount": 4,
   "dts": {
    "definitionLink": {
     "local": [
      "hrow-20230809_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hrow-20230809_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hrow-20230809_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hrow-20230809.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 67,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 3,
   "memberStandard": 0,
   "nsprefix": "hrow",
   "nsuri": "http://harrow.com/20230809",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "AsOf2023-08-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://harrow.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "AsOf2023-08-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 3,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "hrow_CommonStock0.001ParValuePerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, $0.001 par value per share"
       }
      }
     },
     "localname": "CommonStock0.001ParValuePerShareMember",
     "nsuri": "http://harrow.com/20230809",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "hrow_Sec11.875SeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "11.875% Senior Notes due 2027"
       }
      }
     },
     "localname": "Sec11.875SeniorNotesDue2027Member",
     "nsuri": "http://harrow.com/20230809",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "hrow_Sec8.625SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "8.625% Senior Notes due 2026"
       }
      }
     },
     "localname": "Sec8.625SeniorNotesDue2026Member",
     "nsuri": "http://harrow.com/20230809",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://harrow.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001493152-23-027344-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-027344-xbrl.zip
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M_#/635G><!1T20A>)4=^E[!/?]Y>^1W"WF&3+#J@-C9<8&TNB*9C(P13\QL
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M>BG,/MQ/>&LVX7Z$^WE.=J(V13J8^XEO?_9LEJ7JYW3RS,19)B<Y^N7=YLJ
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MA\Q$6Q=\Y$^0M(J,!JY;^+&1G]5OTAD_'C8D)'/G^:Y6KB;-94F%< M#@]2
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M,5MW,IG F\3Z&(=V<N0@VFGEIMZ8:=#J2*;E3S--(@%H8I) B;73"5,RF\B
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M;_MES=M2:][VRYJW)P>AL=)BMY84NUU=G)U>GGX\/GTZ?0J?=AW;I4?G6@K
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M]6YD4R7-$Q6@GW"O0RX&0S<##-G+\'LU_)_OI &"I!EG^]X79405G6:60K:
MX>>2AQ_ZC23JSXK\[FM%G!*EPN\.CN9YH&HGQ.[GN%]"N^OS;I=.!\DZ#B]!
M3+SUT%;4>NOTXE<8/G&^T-0:+VK-7=W#LW!'PHD]75/RI^.FVKO10(#BJ\E5
MC@C508BDS'1@RS'C&8_#%'C_-(BYWFDKGT4.Y/K(DSEDDJFX&!B>5Z-N;4W
M1".D3!+!ZW(3PR1#<,R;I/)3?J01'RW>30_R(HMDZ"^R)$7X Z,.%6!F,>*=
MK2_L+,U58S1/(/'GR.V\/)@A?B^XY$Z<803S_A>[BS"\-<G)X= ?U[>?GONV
M65,XTS$+!(M%@0P\'7#6O2JLGWT7!]1'[Y:V(C'._\S4+S?!'=!!0TQ##ISZ
MJCII8MSU3)59DYJL;ITEQ>AAM0)%!G1CI>5)#!MJ^MJ8O\?W*1HUN4X206(1
M'%4D4\G-5"//C8_F]#""P7.=C?(/7#CA[%<KX.."7@O01$#?P=+A#3 3--0P
M"Y,.#>@[B&"-9IM%PB_.+#<4A/Z\[7#>.N;A QBEVKL?YA-QQM1UZ/'IN6UU
MD+LO-W X+P-$\+R!D]GOG7'=^J2BOC.,N0-,CMB+.W9V(XN7<=R#VNGHNTWA
M4PA3SURR2KLIY0PXK,R/#YTH0_8VN0]DFBIC+$OC"'R$%5,W/[MR^#J,:^[%
M?9VI <3;7ER\QN%;I'#$&.<X3MQ.@CA;IR>(MAN@54+$5T#:(9CO8>FOHG=6
M1HGKN;DEP,?2R2W_0(VXL[9DYF::]!_5"J[*0,+$ZZ[GIXF:]!?2@-V4D72N
M,'JZ"RM^Q+9K?K^@C_6(O$22#>8DX[: %"']?DO5>W5Q3UAUT^[D>[9-_IEG
MT)!9 9)45.[DBN>DPE[7T6%7M1-#IAL*9GT^9^G'P#<#MKG(<'JTA#V2J#;F
M4*T473<_'"E9O)!;H/B6S[U0R,;G[+T8NV<V#NLO;1ZD PL>SUJ=@_Y'"+.6
M4NI^^5BAZXSM[)RRON+6:^R:9=ZPN8R?]8=[(3Q9G8RE(Q WJG#;I'-HJ>,@
MBEM+/&(]W ?G+>MNO_ EN<'"9) %0<S%-V8CT0]6PJ(Z(5;8"B"9.E0!=]9!
M)":+0G13=(TP.."Y.J=UH;-^1,XGFI-8_AC-3VCVQTX4^N. Y!,0T&G(0-=X
MT=/OZ&Q_L2Z! A(YY 0$/=M("*1;<)\7HF>L1*>3Q?(/(S)(;I[100RY@1[W
M]4&4(QVZ$J4AMT'W>8,3-9; BA:1--3E1+@CL#[204:RA&X<UZH_BL_\!([@
MTOM#1HJD_49/XPGLQ =RBJN5]W5R_M/!1L_D'5_THJ',<=_QX*X;N?8V)"$B
M;OEQ'W;<J3A:).?/.3,^VNB)?R1K\QH=.FGJ5Q#",8GOC9[1/>YW#\O[W:7>
M[QZ6][LKO=\U\]O\B]W?WYR1W/W*V?N?(K*1<64G]E@\;9#)Q>^F5Z;<MGLK
MDQ>+K,,,%MRT,!%)-Z=N<9X,N5LZPIX6<9"/I'<P>XU?R,_SO-J^>W^\^9@?
M;SSFQW<>\>.-PQO+:>?S&PU+P_0B&&A@]C!Z:46]]E9S9]=NME[8S;V][85X
M<F(^].0W3H^+-W?_8PGG_/[F^X=I+&>8G:4,@WWY_<T2]N:/OI>H!]N0UG(V
MI+6<#6DM9T-:A0UY>[&,37FT ]-<SOXTE[,_S27L3W%-5G)0C/(^_.D& ^SW
M-XW_0'7FDYAZM?G3[;)[H2_,[-L]/_+BKH\T'N(C.RO\R%R.R(KB-\\HO]$^
MO=V);NR47O12O>C&3NE&EV[T(A-Y=W[QQ]'%2>W]^?F_Z3Q4*Y=71U>G'TX_
M7EUNO,.\'G>&K;WZ(?M$RPR>F\R"O+X454S1EU@NFY'96KC(]^66RI1>Z^NM
M&NZZ^.(Z<1(>+6N?RVEKR@ET6G!7N;B4MF+522,O0;*U[XPDM[DX$DH-LZ&X
MYCKE=%V$8X)TP"5-5N3%7V)=9:T!*!(N.^9\!$Y"-B7;;34. W>ZJIV3KD._
M6&9TPYC5BJOB3N2U4:2(S%E3/\5_XB:/Z+P\/;:ZGH\4"AOYP'U+ES#>,*@5
M*8&)U!E$QW(CFI<QZ^02^C6G6>7ILZA&SLN5\>UY><6QAK&87\W+J4NJTP^X
M@-V4)M,X&N\7^;M= ^PA, ]982,SA\.3!RFTW@'N)R.NB??])UB;]10..YTQ
M8AO+]S1HB[#T,,=K0 G@C8=JR-F_68-M?15^08];[YQ.$J*\7JZ_8]W"3E]>
M3;/U$2.N5"L7"@E12#LAP@9$8^W?MO6?U(E(POAC2WX=%W__'^%12??3)RVO
MWZ7C5S+>6C+>-()!I.+49_"0L<YTMH"Q$+%DT_*5F9'DT'\YLZEN$DU<+^[X
MCC< BXZE0D=XC<1/FZ;%P@T2D[,M%'Z.B'ZL^/D\VT6/#$G(7=MOTV2Z:MUD
M8A-; V/'"R!.'2D7T8DGC$[)];+,HR/ZKH:MF*-$H7WH=,4L1FLQ^DGB1A=E
M[=G(T@:2\5+2B.>#''A'$EZ0(U-R_%IR_)$N).)\0),^BKH8?:6$[N"_'AU]
M*G D64D ?('IH-/Q^30<N2":E/?IV[.KDR.2@.8'RN$:(X99B1BY*H[UU/6/
M A0+!$A-LK9\^NVV+6@[_,NV$^N&6Y(VZ<X^CJ(!22BM6T?(4PT#P/(Y1KIG
MLS"TY\)X$,;(QZ1W$@'&&3H1&RMXGBP&\X*7X?BXF<$IYZ/D[+7D[-=G;SZ&
MJ.Z?"]KA35JBQ#:^?[,%BI0_1J[Q_A;HIW,6M)SV)SA1$\A-*#3+P2+#-&$0
M ?86#%XD0Z/=^$$-\<OU207;1V/]TJ)YUYZ;\K'C-$0!M-185T4\.&9SX\MH
M+*:$\?!&\9-/SWL@F([5\"[Q(Z=MN^+DVHQ, 1 G_4_VBO!K*W &JB"<V)#@
MFJQ.050-4S(Z.EI51UDE*LG-#&K)PXL0Z9RN%8X"KN7=>"99#-UR,T)7'[4>
MJU;>9>KX@]90987_YDRK6,)]4U#%^!Y(=!]J0..87&'DD7N!'&W4Q40N@]FQ
MI&>(,RFS][D>!4T_E-3/I )'/XQ(4GA#5(IN@95@:N7A)X8HS!J(P(=)8Q2'
M.&W2DG:QOH>+6M*$E-G?--24\2<)H##>+F06-CGI3NHR7,^L):E+B$  JM#(
MGNSHOB1SY@BB;2R:0L6)!@J:6;W\(V8=09*NI./!=$4<$/LL73M*?E-,=&@?
MB1[V0I=$X%V3,UAX*%>'PM<1!V-TFFC#G'G/CSU>J)ZV!*J57[G )?5[O!P:
MF0L!!"N/B)HJF=A4'Z NYA;#'?K!1XP2,\_L?VODL":X]A0CMCJL"L!_4BD[
MO<(%IL1G;:DTQMNFGPQ_/C(,(*A1L&ET"07@(1(EA9+<2$%/_Y;#0![PQ&DP
MY;]=B>MHI:@"-P90)S09&C D.2+O_&6[<X,-[7J3NBGI9JX/YH'0B:S@"4>,
M.6'J5Z9G4F1!XZAO>=L"2\5PN6SF,?@43,RL>JXSEE75.IK1+Q1BF@IXG3$@
MQUV!+\TFJ,.].0=P4,HL'_W;)?\-(%\U*9)Y19084K@=FRN'RZ,I=!+C2 %8
MF*P,O>':!U0NR1'\-D+ /))U5X,"*B].=N9G.8F B!A4B'DKQ<Z?IA:":_KL
M8F $9L(V2:E(Z8U'5.(;AY,B6)IZM@V1RI;3"T@C)*E>, %0SE@-)6Z 1(T3
MCGFG@8Z" ZP,'BS]ZN_Y\DDS=-WZ+1RA<,B>]9\GY2<7^^"V@#V/VTZW+EAN
M%V42EQ4Y5LZS1*6&^ P32_^N+3/EVQ(;=B0]#AD8\<.8!:TAV"^4LYI]\6Z!
M7;?>I1$HUUQR$^UFU0M+EJWTB NM]/84/ED(SNF(W.W23P#<R#/40[ DT7(G
M)EOZUI<-@;(-!039_&9F/O,-AHI6-WP,/+A',=+N2']HE.D/RTU_:)3I#P_+
M]4\I)<+HGFI%E,\Z^)(K"*NLAS>Y@HEQCPNC+UW5A:T[:]7&'#C7$7.)G]O:
MSC-Z2]"&6!WR15 -.-UR-:^".+_I02%_$(O>$^!D,A"<K_0#)""0%]GQ](63
M,T##G;_UO\1^8@-DB@XBC0T21C0S:G_*PBP8/P4S4RX"&'*.B1+#LUZMW.8A
MW1[WG]7\L.JF%]2;LZ SWB)PEV*!JBTX+=I&@_$U8:>Q*09X@P3-BCD0!VP[
MOC$!:KO'Z',S7Q4+SI":^TB3=B[?'^).1R7<'<2X-6S0;+%EXP7;^;MFN_BO
MN'J418%OJ/MXJGCFR\5<$&4^Q/#NY3W)^LJ.;F@:M3"@TNP-VNSMWLREFIV!
M^(7B#TV<J.PA<!]XU\Z@E),^<%8$_4SN_6+OJT%#4WP[\J\T4%9KQV9< =O$
M:W*37<=JX'X@$_OE$]RG^0RXH45P<VNH[DX8O\< >B5' ,Y(0)'OWI# ?GR.
M-?OXSQ_VIQ?L1H=CSN W6&M31K/8TSN9>6V^L,/)3\S75WPJ/L@I.,4ID$VW
MOOM_WT",.7=BUZ]H"Y[5MEZ2:'L6F[IPN<^FB8?F\OEHX>K>-3Y>JUF6Q>J.
MG]VRE-SRT-RRZHI2;8"U]J?JYB1\R":TL9R_LS)O[@=^O&'01G/J<48/_>'-
M%DVF><C]O6YX<>YGMM>"]GW:B$VEO;%COSAH;BCQ+^S]@X/[TK[R0GOYVN4B
M<:]O+HB6L>?+V3DKM6?O-N9N\EUCKHJ@AGUXV%HG@HB-=O?6B:!=(F:N4+E]
MS(=$*I"OG^F(K6%F#LFLGJ$/=G;7:;L:]L'A>A&T8^_N-=:)HI:]]V+_@3EZ
M<3E])I'OQ/F:!?ZWVBI072_97O7*;#46%#TKIV1W9YTX9JNULZ"26,N%>7A9
M?%*X*UOY<3Y\L4Z\LMM<*_&[?[A6)^G%[CVLK0>2O$>%*UWNBQTD3M#SN-5X
M'*MDY=9QT[[7\CR;HT7*:6^]N'GG'L[,8UC&678"XBS6EMRN;S^(A7S06"]Y
M:.\<KI5_M=6P6\T%C]G*K8L7)($>FJ5O$M +Q#B%$BE:G.?UW3K4[0&BN\.W
MBR[SMXUDO*:#N2RQ\)I\0^1[K=>A]NQ78-F9%GOVODADZ_7E[Y](_)!0P5^R
M#(QGOM[+X;A5*_D;B+KC2DG;N9,Y3X^T93-!]OO)2426YNKSS6#<Y:S"KKU7
M+D)CWV[MSKV%>4ZK<&COSK\_^#XQ5D RO1\4P62"XF:G';X]OS@YO2AF($ZD
M&4XD*N6SS5.5OB5%$[+_]K(<DZTXUU;/UE-3N%-O+KM>Y$8KXFZREEM[SH6=
ML?7CGKV[ST<@RZ5EKS<,R$= TG?JQ7UVAL,N]_ZK3Y@^PO(W,?PFI'0_I0H>
M%(L"J8ZK1=>A?*>$@O@6R#E4[Q2K??-JTL4ALZ8KG$UES0T@6C< :!61M_*Q
MS*=-53C BXJ5/0+_-ABB&QA#$-%0/17/C0X7:X[BL)N,4,^K.Y[+RV&<H) (
M4^PQ\!Q&!YV*I5->1"2_ 5A2,BY M1;73_]RH))^Z,X.5WB?&Y@R?%.7IJ'[
MF29]\CAZ_6I%5]^85ZTMC?+P[O.G]QKA81L@!X#>02$/ET]9#-2$LG2I6>#/
M_Y+/A.1NS[M60";(A"QZ14J=DRYJF*P$!XBI[AIM-J- KF"NR=( Q3:O_.>E
M-WU941$D94(:P"'KXVHYIM^EU2'.]&1!,$F[@%O(T(@9)*SIH0[\#-\'S)O&
M8N4Q8\:7J)GGN3C+1OU[$M%+*==P:7;YA1X"=F>L6UO&(:[&BB_)&+[JH1:?
M?UBM3"^J<H#*.5^%H8R)_QR$+B/7\6SL NORNAED))OA09*,2X0_N4)%,ZZ-
M JB1 EB3$V?56'FF4!$%H8#,X"K\E#90#36R0 9I@-, G"^@-!;:Y0)8D0'"
M5!$U!,WL\=NVXBZZEE.M_$C&%2MUE-7$0')\@H57=U27-\OJ\MS26$9U>;.L
M+G]@#M^L*2Q61#AIX\R <BY40!A/E0W.*Q>L5M:^7G!=7/1[R*H550;FI0&-
MY=<&W%Q4-UE:^HU!Z4<M75IFB<5<_W1)T:L[ CPK=XTA/:8\8NNIS&V^P[\<
MEKK/ .M1"32=H'2L_9&SW!4]FDA46OH\R_.\.I[/LW2>ZJG^%1[MVISIDB\7
MVS5)KWFJ/'F&.$;)DQNV:_"XGBI'KM3V>:ARW[WYY;X%P*?I":VR<'.ZQZG)
MMV[9NP=S$XIO_<K\,_X8]-O[N]]>[[LVY,]D6I5DKY)9]NU&X_NXY8'J,'XM
MW JN/#M]@4SGGU9-Q-T//F1">DG-+>SR8F%V>?@RC_.I*_)5+T;3;NVM53'_
MVM5/S:B*9T_(GMVX3_G- VF>K?=%\%&YTA/\UU6O"W!G=A<LE%IY%=#:G:,U
MJR&[H3CGL<C9VEL4H&,9B#/W4DU7SE=+@QBL?'/6JKIO;01O2<@R&.6!]-#'
M:2#LAU _\V'/2O53JI^[>&=1P*%'4S_+B\^^G<DWYJS9+,W8VOIQ>[(BXN54
M8>7*MF&GWMA=@].[7@Y[2<VM'+,S@RRZFE.[N.K[@U,/D)Y-HR/U,4@';3I=
MZ-R! \9YS&A*%@8Z%QU]B'6;/7NV'F#5B]@"O!GC/Z[+MJX7DY74+)]WYE5E
MEJF=3S2U<QI8OTSL?.K)#65B9\F3Z[9O$ZFG3Y4Y;T^I+3EVHS;SZ:?3ON?2
MT)(Q-VS;RGS:DB?7;=?*?-HRG_;[4PQW&W9K/B+N9J1([MK[\Z\R-H/\#4U,
MW5"R=_?LP\.Y;22><S[M_N'=H<PRG[:DQMRL+Q#Y?C;YM"U[;W^M\FG7#F]_
M;7*'UH:0%_;^?1JJ/?U\VD;#;ARL2S>CM3M(:]5T($,D7Z/5>3&_D>8:Y30]
M8$KMPMVOGIGP+0E9"J<\V:3:FWO:ECJHU$%WKLY>:\$NE<\RK_;ATFI;^VO
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MJZPM_'X0QHD5*;CC^JI(" F[]"R=QVUKD/J)-_0]>J\]YC'SJR]SX:7#8:-
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M\AY0O:VQZ4=-BX%B$L]"N0.[B\U)'R7<PAW= ']CJ9>RCT1=6W\@KE.S#QZ
M8=$L.C2P<@?]1GG'\-'-K3>@__EW;$_:GP5WPBVL.08)G^.V\%XG/;-%F$R
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M#<U#S<7ZK?F'71U*,;7^</="_38Y!K#N7BSY;8%&FUN?TQZ8IQ;HL'..Z;*
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M(L4B$Z[A*#';]1E]<?Q2?N)'O#AFE!>ZVK309FY'_?;4>]JE2&R5P+Q%NH=
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MWVI/J_WW[/S(WFLG+[Y_=Z?K_P%02P,$%     @ LX )5[D^9U/9 P  B \
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MCO.FE,^3P/\VH9:;%3(NOP-02P,$%     @ LX )5Z<<9HXU"0  H&L  !4
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MF:]&6K=]35YVQK=Q]L\T[^?)R\YT)?*'V,Z:EG<^O>;S&HN-5_Q3S2+99'P
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M:QQ_)"O*VO"IRVQ38S*IPU+5>,6(P1B(AM(B)79$Q+_6F&6$Q<^=4#24MKD
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M^FB_77WC?KB_\&&/_ U02P$"% ,4    " "S@ E7R(B4+30M  !PI0( "@
M            @ $     97@Y.2TQ+FAT;5!+ 0(4 Q0    ( +. "5=/!=3
ML58  .T! P *              "  5PM  !E>#DY+3(N:'1M4$L! A0#%
M  @ LX )5\3I'^HY%@  \[D   L              ( !-80  &9O<FTX+6LN
M:'1M4$L! A0#%     @ LX )5[D^9U/9 P  B \  !$              ( !
MEYH  &AR;W<M,C R,S X,#DN>'-D4$L! A0#%     @ LX )5Z<<9HXU"0
MH&L  !4              ( !GYX  &AR;W<M,C R,S X,#E?9&5F+GAM;%!+
M 0(4 Q0    ( +. "5=FA])T4@P  +64   5              "  0>H  !H
M<F]W+3(P,C,P.# Y7VQA8BYX;6Q02P$"% ,4    " "S@ E7JGD4-',(   S
M9@  %0              @ &,M   :')O=RTR,#(S,#@P.5]P<F4N>&UL4$L%
3!@     '  < L0$  #*]      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
